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ABSTRACT 
Obesity-related insulin resistance is accompanied by impaired microvascular recruitment 
within skeletal muscle.  Loss of recruitment within the microvasculature of the muscle has 
been shown to be an early defect leading to impaired insulin sensitivity and in time skeletal 
muscle insulin resistance, although the mechanism of impairment is unknown.  Both obesity 
and insulin resistance have been associated with chronic low-grade inflammation.  A number 
of inflammatory factors have been shown to directly influence vascular and myocyte 
responses to insulin and may therefore be a contributing factor towards the development of 
insulin resistance.  The aim of this thesis was to investigate whether impaired vascular and 
metabolic responses to insulin are attributed to the presence of inflammation.   
Dietary models of obesity-induced insulin resistance were studied in Sprague Dawley rats.  
Rats were placed on diets of different fat content (41% and 58% calories derived from fat) in 
addition to a cafeteria-style diet.  All diets were given for a 4 week duration, with both high 
fat (58%) and cafeteria-style diets also extended to 12 weeks.  Hyperinsulinemic euglycaemic 
clamps and 1-methyl xanthine (1-MX) techniques were used to measure whole body insulin 
sensitivity and microvascular recruitment, with inflammatory gene expression in the skeletal 
muscle and epididymal adipose tissue measured by quantitative real-time PCR (q-PCR).   
Four weeks of 41% high fat diet caused obesity, insulin resistance, and impaired capillary 
recruitment in rats; however inflammatory markers in epididymal fat were not altered.  
Raising dietary fat content to 58% resulted in increased adiposity of the epididymal fat pad 
but did not cause insulin resistance or inflammation of adipose tissue.  Long term feeding 
with this diet attenuated obesity and these animals did not differ from paired control diet rats 
in insulin sensitivity or adipose tissue inflammation.  A more palatable and varied cafeteria 
diet resulted in even greater obesity and insulin resistance than the 41% high fat diet and this 
was sustained after 12 weeks of feeding.  However this diet did not cause inflammation after 
either 4 or 12 weeks of dietary intervention.  Finally, restoration of muscle insulin sensitivity 
by metformin in 41% high fat fed rats was tested to see if adipose tissue inflammation could 
be reduced.  Metformin was found to significantly improve insulin sensitivity in insulin 
resistant rats after 4 weeks of high fat feeding with the 41% diet, and significantly improve 
skeletal muscle microvascular recruitment compared to that of control animals.  Therefore in 
addition to its known glucoregulatory actions, this study has shown metformin to have 
ix 
significant actions directly on the vasculature and can restore microvascular blood flow 
within insulin resistant skeletal muscle.  However, these improvements were not 
accompanied by attenuation of adipose inflammatory gene expression.   
The lack of up-regulated inflammatory responses in insulin-sensitive tissues of obese and 
insulin resistant rats suggests that inflammation may not be a driving factor for the 
development of metabolic or vascular dysfunction present in insulin resistance in rats.  The 
lack of inflammatory response despite significant obesity suggests that rats may possess 
mechanisms protecting against obesity-induced inflammation.  Adipose tissue 
microenvironment and expansion have been identified as potential mechanisms regulating the 
induction of inflammation with evidence suggesting that adipose tissue can undergo both 
healthy and unhealthy expansion in response to lipid accumulation.  Data presented in this 
thesis suggest that in rats adipose tissue expansion occurs in a manner that protects against 
the development of inflammation, although further investigation is required to identify such 
potentially protective mechanisms involved in obesity-induced adipose tissue expansion.   
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PREFACE 
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CHAPTER 1 
INTRODUCTION 
2 
1.1  Diabetes 
Type 2 Diabetes is rapidly reaching epidemic proportions and becoming a serious health 
problem worldwide due to the high prevalence of obesity [1, 2].  In 2013, diabetes was 
predicted to affect approximately 382 million people worldwide, with this number expected 
to increase to 592 million by 2035.  It is believed the more than 85-90% of those affected are 
suffering from Type 2 Diabetes [3, 4].  A study conducted by Shaw et al [5] estimating the 
global prevalence of diabetes between 2010 and 2030 predicts a 20% increase in diabetes 
diagnosis in developed countries within this timeframe, however most alarming is the 
predicted 69% increase of diabetes diagnosis to occur within developing countries [5].  
Despite this prediction the increasing burden of diabetes is expected to remain within 
developed countries [6].  There has also been a growing trend in the prevalence of Type 2 
Diabetes reported in children and adolescents [7, 8].  Twenty years ago approximately only 
3% of diabetes diagnosis in children was classified as Type 2, while today that number has 
increased to more than 75% of childhood diabetes diagnosed as Type 2 Diabetes [7, 9, 10].  
All studies investigating the development of diabetes agree it is a growing problem and 
considerable additional work will be placed on the healthcare system if these trends continue 
as Type 2 Diabetes is currently one of the leading causes of mortality in the Western world 
[11, 12].   
Both obesity and Type 2 Diabetes are associated with the development of insulin resistance, 
which is characterised by impaired insulin signalling and response within insulin-sensitive 
tissues such as skeletal muscle [13-16].  This leads to poor uptake of glucose by the body 
tissues, resulting in high blood glucose levels and hyperglycaemia [13, 17].  Abdominal 
obesity in particular is associated with insulin resistance in skeletal muscle, adipose tissue 
and the liver [18, 19], with insulin resistance within these tissues often present years before 
the development and diagnosis of Type 2 Diabetes [20].  In addition to its metabolic actions, 
insulin also has important action on vascular responses by controlling blood flow and the 
delivery of both glucose and insulin to the skeletal muscle.  In insulin resistant conditions 
these vascular actions are impaired which further contributes towards the development of 
muscle insulin resistance [15, 21-23].  This vascular dysfunction has been associated with 
other health complications such as cardiovascular disease, hypertension and atherosclerosis 
[14].  Dysfunction within large blood vessels (macrovascular) is found to occur in conditions 
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such as arterial disease and stroke, whilst dysfunction of smaller blood vessels 
(microvascular) can result in nerve damage (neuropathy), kidney disease (nephropathy) and 
complications and damage to the eyes (retinopathy) depending on the specific location [24].   
 
Obesity, Type 2 Diabetes and insulin resistance are proposed as being states of chronic low 
grade inflammation.  This presence of background inflammation is thought to be an 
influential factor contributing towards altered insulin signalling seen in obesity and insulin 
resistance [19, 25-28].  Although a number of potential mechanisms have been proposed and 
identified, it is unclear how rapidly inflammation develops in diet-induced obesity, and 
whether it has the potential to impair microvascular responses at early stages of insulin 
resistance and thus contribute towards impaired metabolic responses.  A number of studies 
propose inflammation to be a potential driving force which initiates the dysfunction present 
in these states [18, 27-29].  Significant progress has been made to understand how and why 
insulin resistance and the subsequent progression to diabetes develops [15, 18, 22, 30-32], 
however the exact mechanisms by which insulin resistance occurs at a molecular and 
signalling level, in both the skeletal muscle and vasculature, still remains to be confirmed.   
 
 
1.2  Insulin  
Insulin is a hormone produced by the pancreas in response to high levels of glucose in the 
blood [33, 34], such as after a meal.  In order to maintain glucose homeostasis, insulin 
promotes skeletal muscle and adipose tissue to take up glucose from the blood, while 
suppressing hepatic glucose output by the liver [33].  Skeletal muscle is of high importance 
for returning blood glucose levels to fasting levels as it accounts for approximately 80% of 
whole body insulin-mediated glucose uptake following a meal [35].  In liver and skeletal 
muscle, glucose is stored as glycogen – a long-term energy store that can act as a reservoir of 
glucose for muscle cells when availability is low [36, 37].  Liver glycogen is able to provide 
glucose to the rest of the body for fuel when circulating blood glucose levels fall via 
gluconeogenesis [38].   
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The actions of insulin depend on its binding to specific receptors which are expressed on the 
surface of most cells in the body [39, 40].  This binding initiates a complex signalling cascade 
collectively known as the insulin signalling pathway [41] (Figure 1.1).  Insulin is able to 
signal through a number of pathways including Grb/Sos, MAPK, and TOR, however the most 
relevant signalling pathway for metabolism is by PI3K/Akt.  The insulin signalling pathway 
is highly complex and consists of multiple feedback loops and interactions between signalling 
branches and receptors [42, 43].  Many previous studies have investigated this response in 
order to gain understanding of the signalling pathways by which insulin promotes glucose 
uptake and allow greater insight into insulin’s actions within various tissues.  [22, 34, 39-41, 
44-49].    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 – Comparison of metabolic and vascular insulin signalling pathways 
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1.2.1  Metabolic actions of Insulin   
The insulin signalling pathway is initiated by the binding of insulin to the insulin receptor 
(IR) which activates tyrosine domains and causes its auto-phosphorylation [45].  The IR 
becomes activated and is able to bind and phosphorylate insulin receptor substrate proteins 
(IRS) which act as docking sites for other signalling molecules downstream in the pathway 
[45, 49].  Tyrosine phosphorylation of IRS creates recognition sites to allow binding of 
phosphatidylinositol 3-kinase (PI3K) at SH2 domains [50], resulting in the activation of PI3K 
and generation of phosphatidylinositol 3,4,5-triphosphate (PIP3).  PIP3 activates a series of 
serine kinases including 3-phosphoinositide-dependent protein kinase-1 (PDK-1) which 
becomes activated and can then go on to phosphorylate and activate other serine-threonine 
kinases downstream in the pathway such as Akt [2, 40, 51-55].  Activated Akt is then able to 
phosphorylate AS160.  Phosphorylation of AS160 is required for GLUT4 translocation to the 
cell surface, allowing for glucose uptake in the skeletal muscle and adipose tissue [56-60] 
(Figure 1.1).  This translocation of GLUT4 is a major rate-limiting step for glucose uptake in 
skeletal muscle and adipose tissue [56, 61, 62].  Inhibition or altered associations of any of 
the key signalling molecules in the PI3K signalling pathway have the potential to prevent 
GLUT4 translocation and therefore limit the amount of glucose that can be taken up by the 
cells and tissues in response to insulin.  Akt is also able to activate glycogen synthesis by 
inhibiting GSK-3β so that glucose it taken up by adipose and skeletal muscle, and can be 
stored for future energy use when circulating glucose levels fall [52, 63, 64].   
 
As outlined, insulin not only stimulates the PI3K signalling pathway to initiate glucose 
uptake and removal from the circulation, but it also has actions on the vasculature to promote 
vasodilation [47, 51, 65].  In the vascular endothelium, insulin is able to signal through the 
PI3K pathway to stimulate the production of the potent vasodilator nitric oxide (NO) [47, 51, 
66].  This resulting vasodilation increases blood flow to skeletal muscle thereby allowing for 
enhanced glucose uptake [23, 67].  As well as being a potent vasodilator, NO also functions 
as an important signalling molecule in other pathways and can be produced by almost all 
cells in the body [68-70].  There are three nitric oxide synthase (NOS) isoforms: neuronal 
(nNOS), endothelial (eNOS) and inducible (iNOS).  Both nNOS and eNOS isoforms are 
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expressed constitutively, while as its name suggests, iNOS expression occurs only when it is 
induced, usually by inflammation [68, 70-72].   
 
Insulin-initiated production of NO occurs through activation of the PI3K signalling pathway 
and shares similar initial signalling cascades as those required for glucose uptake by skeletal 
muscle – the binding of insulin to the IR, phosphorylation of IRS followed by binding and 
phosphorylation of PI3K.  PI3K stimulates the production of PIP3 which phosphorylates and 
activates PDK which in turn phosphorylates and activates Akt [13, 73].  However, the 
difference in the signalling pathway between the metabolic and vascular actions of insulin 
differs at this key signalling molecule as instead of Akt activating GLUT4 resulting in the 
subsequent uptake of glucose by myocytes, Akt activates another branch of signalling by 
directly phosphorylating eNOS on the serine 1177 residue [51, 74, 75] which stimulates 
eNOS to release NO, resulting in vasodilation (Figure 1.1).  This is an important action of 
insulin as increased vasodilation results in increased blood flow to skeletal muscle, which not 
only increases the delivery and uptake of glucose by skeletal muscle but also increases the 
delivery of insulin itself to facilitate glucose uptake and insulin delivery to myocytes [44, 51].   
 
Insulin is able to signal through a pathway other than PI3K to elicit other vascular responses 
such as vasoconstriction [2].  Insulin is able to signal through the MAP-kinase (MAPK) 
pathway (Figure 1.1) to activate the secretion of endothelin-1 (ET-1), a powerful 
vasoconstrictor, in the vasculature [66].  This signalling acts concurrently with insulin’s 
ability to promote vasodilation through eNOS in order to maintain vascular function and 
provide regulation of blood flow by controlling the dilation and constriction of the 
vasculature. Following the activation and auto-phosphorylation of the insulin receptor (IR), 
insulin is able to phosphorylate and bind to insulin receptor substrates (IRS).  Tyrosine 
phosphorylated IRS binds to SH2 domains and activates Sos, which in turn activates the GTP 
binding protein Ras and begins a series of kinase phosphorylation cascades involving Raf and 
MAPK [41, 55, 76, 77].  It is this activation which stimulates ET-1 to be produced.  
However, signalling through the MAP-kinase pathway to produce ET-1 has not been as 
extensively studied as insulin signalling through the PI3K pathway to produce NO, so little is 
known about the exact details of how ET-1 secretion is regulated [72].  Despite this, these 
mechanisms of insulin signalling in the vasculature are highly important in regulating the net 
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vascular response to insulin [66, 78].  An imbalance of vasodilation or vasoconstriction in the 
vasculature may lead to impaired vascular delivery and as a result, the development of insulin 
resistance [2, 31, 78-81].   
 
1.2.2  Vascular actions of Insulin 
Insulin is reported to have two types of control within the vasculature of skeletal muscle: to 
increase artery blood flow and to increase microvascular capillary recruitment [22, 82, 83].  
In the past, increased total blood flow has been suggested to be important in insulin-mediated 
glucose uptake in skeletal muscle since it was thought to enhance the delivery of insulin and 
glucose to the muscle cells [84].  However it has now come to light that the distribution of 
blood flow within skeletal muscle may have a more significant effect on glucose uptake than 
bulk flow itself [16, 21-23, 32, 44, 56, 85, 86].  These studies suggest that microvascular 
blood flow is critical for glucose uptake within the skeletal muscle as opposed to increased 
total blood flow.  Insulin-mediated vasodilation occurs in distinct stages.  Terminal arterioles 
are dilated first, resulting in an increased number of capillaries receiving blood flow.  This 
process is referred to as microvascular recruitment and leads to a redistribution of blood flow 
in muscle without altering total blood flow to the muscle.  Following this, relaxation of larger 
vessels results in an increase in the overall net blood flow to muscle [22, 23, 87].  This 
microvascular action of insulin was first characterised in the skeletal muscle of rodents [23] 
and again more recently confirmed in the human forearm [85, 88].   
 
A concept championed by Clark and Rattigan et al [23] is that capillary recruitment occurs 
via redistribution of microvascular blood flow between two flow routes.  Early studies using 
the rat perfused hindlimb support the idea of two flow routes being present in skeletal muscle, 
nutritive and non-nutritive flow [67, 83, 89].  One flow route has close contact with the 
myocytes and is able to exchange nutrients easily so is regarded as the nutritive flow path.  
The other flow route has very little to no contact with myocytes and instead has more 
interaction with connective tissue and adipocytes.  Because of this, it is viewed as non-
nutritive flow.  It has been shown that non-nutritive vessels have the ability to carry a flow 
reserve which allows blood to be redistributed into the nutritive flow paths during activities 
considered to be of high metabolic demand, such as during exercise [67, 89].  This 
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redistribution of flow into a nutritive flow path where there is more contact with myocytes 
allows for a greater uptake of glucose from the blood into muscle cells.  Because of this, 
insulin has been shown to have the capacity to change and redistribute blood flow from the 
non-nutritive to a nutritive flow route so that there is greater contact and opportunity for 
glucose to be taken up by the skeletal muscle [22, 67, 89].   
 
In healthy conditions, insulin is believed to increase total blood flow and microvascular 
recruitment via a PI3K-dependent pathway in order to enhance glucose uptake by muscle 
cells [44].  However, it is difficult to confirm the exact processes that lead to microvascular 
recruitment occurring because a functioning intact model with signalling between skeletal 
muscle and microvasculature is needed.  Therefore insulin-mediated microvascular 
recruitment has largely been studied in vivo [22, 23, 32, 90, 91].  Such studies have shown 
that insulin has the ability to increase total blood flow and microvascular recruitment in 
skeletal muscle, but it is this microvascular recruitment that has been revealed to be 
responsible for increasing muscle glucose uptake [23, 32].  Inhibition of PI3K with 
wortmannin has been found to block insulin-mediated microvascular recruitment [90].  
Insulin-mediated glucose uptake is also found to be inhibited when microvascular recruitment 
is blocked by α-methyl serotonin or by the nitric oxide synthase inhibitor N(G)-Nitro-L-
arginine methyl ester (L-NAME) [92-94].  Vasodilators have been shown to increase blood 
flow in both normal and insulin resistant skeletal muscle, however this increase in flow was 
not shown to enhance glucose uptake [16, 23, 92].  A study by Mahajan et al. [95] comparing 
nitric oxide vasodilators showed that the vasodilators bradykinin and methachonine both 
increased blood flow, however only methacholine enhanced microvascular recruitment and 
skeletal muscle glucose uptake.  These results indicate that methacholine acts upon different 
specific sites within the muscle vasculature in order to enhance recruitment as opposed to 
other vasodilators which do not.  Currently methacholine is the only vasodilator that increases 
both total blood flow and insulin-mediated glucose uptake in the skeletal muscle [16, 78].  
From these data, recruitment of the vasculature appears to be independent of changes in total 
blood flow which are also caused by insulin [44, 82, 87]. [82, 87].  It has even been observed 
that insulin-mediated microvascular recruitment occurs before changes in total blood flow in 
muscle [32].  This raises the possibility that insulin may have the potential to use different 
mechanisms to recruit macrovessels which control total blood flow and microvessels which 
control capillary flow in the muscle [87].  Further studies into microvascular flow and 
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insulin-mediated vascular recruitment are needed to bring more clarity to this area of 
research.   
 
1.3  Insulin Resistance   
Insulin resistance is characterised by decreased sensitivity of tissues to insulin.  Insulin is 
therefore unable to suppress hepatic glucose output by the liver or initiate glucose uptake in 
skeletal muscle and adipose tissue [13, 37, 48, 52, 96].  This leads to high circulating levels 
of glucose in the blood,  known as hyperglycaemia, which has been shown to be involved in 
the signalling dysfunction and chronic inflammation present in insulin resistant states [2, 13, 
97].  This dysfunction in insulin response may be present for a number of years before the 
development of abnormal plasma glucose levels which lead to the diagnosis of insulin 
resistance and Type 2 Diabetes, as well as other conditions such as hypertension and 
cardiovascular disease [91, 98].   
 
1.3.1  Metabolic Insulin Resistance   
During the development of insulin resistance it has been proposed that the liver and skeletal 
muscle both become resistant to the actions of insulin at an early stage.  As insulin resistance 
progresses, insulin is unable to suppress glucose output by the liver or stimulate glucose 
uptake by the skeletal muscle.  This results in the glucose concentrations within the blood to 
rise, which in turn stimulates the pancreas to increase insulin secretion in order to try and 
maintain euglycaemia.  This is often referred to as compensatory hyperinsulinemia.  Initially 
this increased insulin secretion by the pancreas is able to maintain normal blood glucose 
concentrations, however over time either the production of insulin by the pancreas or the 
responsiveness to insulin action itself is reduced, resulting in hyperglycaemia that can no 
longer be controlled by normal means.     
 
Insulin resistance is characterised by the impaired insulin response or insulin signalling.  It 
has been identified that skeletal muscle from obese and insulin resistant subjects show 
selective impairment in insulin signalling pathways; specifically through the PI3K/Akt 
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pathway as opposed to the MAPK pathway which maintains normal insulin signalling 
responses.  Selective defects within the PI3K signalling pathway specifically inhibit the 
stimulation of glucose uptake by skeletal muscle and adipose tissue, in addition to insulin-
mediated vascular responses [30, 99, 100].  Impairment of insulin signalling within this 
pathway may be due to a defect of the insulin receptor itself or in receptor expression, ligand 
binding, phosphorylation and tyrosine kinase activity of other downstream signalling 
molecules such as IRS, PI3K, Akt or GLUT4 [33, 101].  Reduced signalling through the 
PI3K pathway results in reduced activation of GLUT4, which is a major rate-limiting step for 
glucose uptake in skeletal muscle and adipose tissue as reduced GLUT4 translocation limits 
the amount of glucose that can be taken up by the cell and tissue [56].  In regards to 
implications on vascular responses, impaired insulin signalling through the PI3K pathways 
also limits the production of nitric oxide in order to stimulate vasodilation within the 
vasculature.  As insulin signalling through the MAPK pathway remains unaffected this means 
that the production of ET-1, and thus vasoconstriction, is unaltered which can results in the 
dysfunction of vascular responses within the endothelium often characterised in obese and 
insulin resistant subjects.   
 
Insulin resistance has also been characterised by the increased presence of increased fatty 
acids and pro-inflammatory factors such as cytokines and macrophages.  Obesity and insulin 
resistance are associated with increased lipolysis within the adipose tissue, resulting in an 
increased production of fatty acids.  It has been proposed that increased circulating levels of 
free fatty acids (FFA) may contribute towards the development of insulin resistance [91, 102-
104].  In healthy states, insulin stimulated the synthesis and storage of fatty acids in adipose 
tissue, but in insulin resistant conditions, the adipose tissue becomes insulin resistant itself, so 
the uptake of FFA becomes impaired, resulting in the rise of circulating FFA levels in the 
plasma [105].  Consequently FFA and triglycerides have been shown to accumulate in non-
adipose tissues, such as skeletal muscle, due to their high levels in the blood.  This uptake of 
FFA is thought to occur due to altered function of lipid transporter proteins, suggesting an 
impairment in fat disposal as much as an increased uptake of FFA and triglycerides by other 
tissues [106].  This accumulation of FFA within insulin-sensitive tissues is closely associated 
with insulin resistance.  This type of exposure of skeletal muscle to high cellular levels of 
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FFA can result in impaired insulin signalling by preventing full activation of signalling 
molecules in the PI3K pathway, such as IRS, PI3K, PDK or Akt [103, 107].   
 
Exposure to FFA and triglycerides increases levels of diacylglycerols (DAGs) and ceramides, 
which can activate kinases such as PKC, IKKβ, and JNK, as well as transcription factors such 
as NF-Kβ.  Each of these in turn have been found to cause insulin resistance by inhibiting 
insulin signalling at various sites [18, 29, 108, 109].  Increased expression of JNK and IKKβ 
have been found in the liver [18, 110], as well as skeletal muscle and adipose tissue during 
obesity [18, 111].    Evidence to support their activation in the development of insulin 
resistance can be given through the use of transgenic animal models.  Transgenic knockout of 
JNK results in the improvement of insulin sensitivity of high fat fed mice and the 
development of obesity [111], whilst transgenic mice with constitutively activated IKKβ 
transgene within the liver have impaired hepatic insulin sensitivity, impaired skeletal muscle 
insulin sensitivity, hyperglycaemia, and increased liver inflammation [112].     
 
Exogenous infusions of FFA and DAG have been shown to block the activation of IRS in 
skeletal muscle of rodent models [103, 107, 113].  The modifications to insulin signalling 
include reduced tyrosine phosphorylation of IRS and increased IRS serine phosphorylation.  
This decreases the ability of IRS to associate with PI3K, thereby reducing its activity and 
resulting in a decreased ability of insulin to stimulate glucose uptake in skeletal muscle.  
Muscle samples taken from Type 2 Diabetic and insulin-resistant obese subjects have been 
shown to have this decrease in IRS tyrosine phosphorylation and reduced IRS/PI3K 
association in response to insulin [114, 115].  As well as their association with the 
development of muscle insulin resistance, increased levels of FFA, DAG, ceramide and 
kinases are also associated with endothelial dysfunction and inflammation [18, 19, 29, 91, 
116-119].  Insulin resistance has also been associated with the accumulation of fat within 
other tissues such as the liver and skeletal muscle.  This increased fat in non-adipose tissue 
can result in lipotoxicity which can further contribute towards the dysfunction of both 
metabolic and vascular actions.   
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Insulin resistance has also been strongly associated with the increased production and 
initiation of inflammatory factors within the adipose tissue [26, 27, 120-124].  Their 
increased expression has been proposed to contribute towards impairing both insulin-
mediated metabolic and vascular responses.  A number of inflammatory factors including 
iNOS, TNFα, IL-6, and macrophage chemotactic factor MCP-1 have been shown to impair 
the normal actions of insulin within both the muscle and vasculature [26, 29, 125-130].  
Exogenously infused TNFα has also been shown to impair vascular responses such as 
capillary recruitment in non-obese rats [126].  This suggests that the vasculature has the 
potential to be highly sensitive to inflammatory responses [22, 23, 131-133].  Although 
obesity-associated inflammation has been investigated within the literature, much is still 
unknown about the mechanisms surrounding its induction in insulin resistant states.  So far 
the contribution of inflammatory factors towards the development of vascular insulin 
resistance has only been partially investigated, and it is not clear whether microvascular 
blood flow responses within skeletal muscle are affected by this increased inflammation 
expression.  A time course examining the relationship between inflammation and impaired 
insulin sensitivity, especially within the vasculature, as a result of diet-induced obesity has 
not been researched by others studying blood flow and microvascular recruitment as of yet.  
Due to shared insulin-mediated signalling pathways, it is logical that inflammation can have a 
significant effect on vascular responses within muscle.   
 
1.3.2  Vascular Insulin Resistance   
Obese or Type 2 Diabetic subjects are regularly found to have some form of irregularity in 
endothelial or vascular function [16, 91, 134].  Diabetic individuals have shown to have 
reduced production and response to NO even before diagnosis, and it is extremely likely that 
some impairment to endothelial function has already been established early in the disease 
progression [91].  Endothelial dysfunction is defined as the partial or complete loss of 
balance between vasoconstriction and vasodilation of blood vessels [91, 135, 136].  It is 
considered to be an important event in the development of vascular complications present in 
diabetes and the development of insulin resistance.  By the time Type 2 Diabetes is 
diagnosed, it is expected that endothelial function is already severely impaired [91].   
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Insulin resistance not only results in impaired metabolic actions to stimulate glucose uptake, 
but also a reduced ability of insulin to signal through the PI3K pathway to initiate NO 
production and vasodilation [13-16, 44, 56, 116, 137].  Although insulin has impaired 
signalling through the PI3K pathway, the other branch of insulin signalling in the vasculature 
via MAPK remains unaffected or even enhanced in insulin resistance [2].  Therefore, insulin 
is able to signal through the MAPK pathway, resulting in increased ET-1 secretion and 
heightened vasoconstriction of the vasculature.  The imbalance between signalling through 
the PI3K and MAPK pathways contributes to both the impaired vascular and metabolic 
actions of insulin [81].  Insulin’s ability to increase blood flow and glucose uptake in skeletal 
muscle has been found to be inhibited in insulin resistant, obese and diabetic subjects due to 
the imbalance and altered vascular responses that occur as a result of the inhibition of insulin 
signalling through the PI3K pathway [117].   
 
It has been proposed that the insulin resistance in skeletal muscle is at least partly due to 
impairment of insulin-mediated vascular responses [56, 136, 138].  This is because before 
insulin can stimulate the PI3K signalling pathway to initiate glucose uptake in muscle cells, 
insulin first needs to be delivered to the muscle via the vasculature [49, 56].  An increase in 
blood flow and vascular recruitment in skeletal muscle is dependent on the production of NO 
in the vasculature for vasodilation [32, 139, 140].  In insulin resistant conditions, there is a 
defect in insulin’s ability to signal through the PI3K pathway, which prevents the production 
of NO in the vascular endothelium.  This results in decreased vasodilation and blood flow 
which in turn impairs the delivery of insulin and glucose to the skeletal muscle.  Therefore 
insulin resistance can be characterised by impairment of PI3K signalling in both metabolic 
and vascular insulin target tissues [139, 141].  Expression of pro-inflammatory cytokines 
such as TNF-α and accumulation of FFA have been found to alter insulin vasodilator 
signalling by reducing the binding and activation of PI3K in response to insulin, resulting in 
reduced activation of downstream effectors such as Akt and eNOS in endothelial cells which 
normally activate the production of NO [18, 28, 91, 117].   
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1.3.3  Inflammation in Insulin Resistance   
Obesity associated with Type 2 Diabetes has been shown to coexist with a state of chronic 
low grade inflammation, and insulin resistance related to obesity has been found to correlate 
with this chronic tissue inflammation [19, 26, 119, 124].  Studies that have specifically 
altered the degree of inflammation have noted reciprocal effects on insulin sensitivity.  Many 
studies investigating genetic knockout models for inflammatory markers such as iNOS and 
MCP-1 have shown a significant improvement in whole body insulin sensitivity in response 
to high fat feeding compared to wild-type controls [71, 122, 127, 129, 142].  In comparison, 
studies have also shown that acute infusion of markers such as TNFα and IL-6 can directly 
impair insulin-mediated glucose uptake by the skeletal muscle as well as insulin-mediated 
vascular responses in non-obese animals [126, 130, 143, 144].  It is therefore assumed that 
this inflammatory state contributes to insulin resistance, however there is some debate as to 
whether inflammation aids in the development of insulin resistance, or if insulin resistance 
itself initiates inflammation in diet-induced obesity [26].  Numerous studies have attempted 
to determine why inflammation occurs in insulin resistant states related to obesity, and what 
implication this has on its development and progression.  Rodent models fed a high-fat diet to 
induce obesity have been used to assess the natural development of inflammation and 
impaired insulin response in vascular tissue, liver, adipose tissue and skeletal muscle [26, 
117].     
 
Obesity has been associated with high infiltration and accumulation of macrophages within 
the adipose tissue.  Macrophages have the ability to induce and secrete a range of pro-
inflammatory cytokines which cause tissue inflammation and signal the production of other 
pro-inflammatory molecules [19, 26, 27, 119, 124, 145].  Therefore the accumulation of 
macrophages into adipose tissue is a potential sign that an inflammatory response has already 
been initiated.  Monocyte chemoattractant protein 1 (MCP-1) is an adipokine that recruits the 
infiltration of macrophages and other pro-inflammatory cells into tissues to elicit an 
inflammatory response.  It has been found to have significant expression within adipose 
tissue in obese states [122].  Studies have shown that skeletal muscle cultured with MCP-1 
results in reduced glucose uptake by the muscle cells [146] and that MCP-1 knockout mice 
fed a high fat diet show reduced accumulation of macrophage markers within the adipose 
tissue, and whole body insulin sensitivity of these mice are improved compared to high fat 
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fed controls [122].  These results suggest that MCP-1 is influential in the induction of 
inflammation in obesity due to its ability to recruit macrophages to induce a pro-
inflammatory response, however MCP-1 may also play a direct role towards impairing 
insulin-mediated responses.  Some of the inflammatory cytokines induced by macrophages 
and reported to have strong associations with obesity and insulin resistance include TNF-α, 
IL-1β and IL-6 [18, 124, 126, 130].   
 
Cytokines IL-6 and IL-1β are strong pro-inflammatory signals which can be used as markers 
and predictors of Type 2 Diabetes in humans [147].  Both have been widely studied and are 
closely linked to inflammation and the development of endothelial dysfunction [27, 124, 145, 
148].  Visceral fat accumulation, which is highly correlated with obese states and insulin 
resistance, has been shown to be an important site for the secretion of IL-6, with its 
production being at least three times higher in abdominal adipose tissue that in subcutaneous 
tissue [118].  Exogenous infusion of IL-6 in vivo has shown to reduce insulin-mediated 
glucose uptake in the skeletal muscle by reducing association of IRS with PI3K by promoting 
serine phosphorylation instead of tyrosine phosphorylation on the IRS.  IL-6 has also been 
reported to inhibit gene transcription of IRS, GLUT4 activation, as well as increase the level 
of fatty acyl-CoA in the skeletal muscle [130, 144].   
 
TNF-α is a pro-inflammatory cytokine which is produced by macrophages, but is also found 
to be highly expressed in adipose and skeletal muscle of obese and insulin resistant subjects 
[18, 102, 149], and is believed to contribute towards these conditions and the development of 
Type 2 Diabetes [124].  Treatment with TNF-α in the skeletal muscle and liver results in 
decreased tyrosine phosphorylation of IRS and increased serine phosphorylation instead.  
Phosphorylation of serine residues on IRS interferes with insulin-stimulated tyrosine 
phosphorylation by the IR [150, 151].  This type of modification to IRS prevents further 
associations with downstream effectors in the insulin signalling pathway, such as PI3K, in 
response to insulin [152].  TNF-α and FFA have been shown to reduce insulin’s ability to 
recruitment the microvasculature in the skeletal muscle [13].  Increased levels of TNF-α has 
been found to downregulate vasodilator pathways by causing reduced binding and activation 
of PI3K in response to insulin [152], resulting in reduced activation of downstream effectors 
such as Akt and eNOS in endothelial cells which activate the production of NO [2].  Acute 
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infusion of TNF-α [143, 152] and FFA [103, 107] into rodent models leads to insulin 
resistance, decreased glucose uptake and reduced microvasculature recruitment.  It has been 
found that mice lacking TNF-α or TNF-α receptors  have better insulin sensitivity if fed a 
high fat diet or are genetically altered obese models [149].  Acute infusion of TNFα has been 
shown to directly impair insulin-mediated haemodynamic responses in non-obese rats by 
preventing capillary recruitment, thereby resulting in decreased whole body insulin 
sensitivity due to the direct impairment of glucose uptake by skeletal muscle [126, 143].  This 
demonstration of exogenous TNFα being able to significantly impact vascular responses 
without obesity-associated insulin resistance highlights the sensitivity of the vasculature to 
inflammatory responses.   
 
Inducible nitric oxide synthase (iNOS) is one of the 3 nitric oxide synthase (NOS) isoforms, 
and the only one which is Ca
2+
-independent [153].  It is also the only NOS isoform expressed 
when it is specifically activated, in contrast to the other isoforms which are constitutively 
expressed [56, 72].  It was first identified in macrophages and was found to contribute to the 
cytotoxic actions they have in immune cells, but iNOS is now known to be expressed at low 
levels in other tissues of healthy individuals [154].  However high expression of iNOS 
appears to be detrimental with induced iNOS expression found in a number of conditions 
associated with inflammation such as diabetes, atherosclerosis, obesity and insulin resistance 
[149, 155, 156].  Increased iNOS expression is promoted by pro-inflammatory cytokines such 
as TNF-α and IL-6, which are also reported to be present in insulin resistant states [72, 157, 
158].   
 
High levels of iNOS expression have been observed in skeletal muscle of mice placed on 
high fat diets, with similar increases in iNOS expression seen in skeletal muscle of patients 
with Type 2 Diabetes [156, 159].  This over-expression of iNOS in genetic and high-fat diet 
models of obesity has been shown to play a crucial part in the development of insulin 
resistance.  Disruption of iNOS in knockout mouse models has shown to be prevented from 
developing obesity-induced insulin resistance body wide [142, 149].  Although they develop 
obesity if placed on a high fat diet, iNOS knockout mice otherwise show protection from 
insulin resistance induced by high fat feeding with improved glucose tolerance and insulin 
sensitivity [149].  This may be due to insulin signalling through the PI3K pathway appeared 
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to be intact in these animals, with no alterations in phosphorylation, association or activation 
of any of the key signalling molecules [149].  This suggests that in normal high-fat models, 
iNOS impairs insulin signalling to PI3K, preventing activation of Akt which is important for 
glucose transport signalling, resulting in decreased glucose uptake.  A similar increase in 
iNOS expression has also been seen in the skeletal muscle of patients with Type 2 Diabetes 
which may contribute to the disease state [156, 159].  iNOS is able to produce 1000-fold 
more NO than any other NO isoform and once it is expressed, its activity is continuous for 
many hours [153].  Therefore, if iNOS expression is induced in inflammatory and insulin 
resistant states, it is possible that the excessive NO production interferes with the highly 
coordinated actions of the vasculature and contributes towards the endothelial dysfunction 
seen in such conditions [158, 160-162].  The rise of pro-inflammatory cytokines associated 
with inflammation and insulin resistance may also alter the expression of iNOS in the 
vasculature [72], which would affect the regulation of vascular function.  Increased iNOS 
expression is believed to interfere with the highly coordinated actions of the vasculature [158, 
160-162], however its involvement in vasoconstrictor responses is less studied than the 
involvement it has in insulin-mediated glucose uptake in insulin resistance [142, 154]. 
 
Inflammation has not only been found to contribute to the formation of insulin resistance but 
also to endothelial dysfunction of the vasculature [13, 14, 16].  While there have been reports 
from high fat-fed mouse models that inflammation is a late development, changes in 
inflammatory markers have been shown to also occur early in the time course, albeit much 
smaller changes [26].  It is unclear from rat models and human obesity how rapidly 
inflammation develops, and thus whether it has the potential to impair microvascular 
responses at early stages of insulin resistance.  In a study by Kim et. al [117], it was found 
that the vascular tissue is affected much sooner in the development of diet-induced obesity 
than other tissues involved in glucose metabolism.  A number of inflammatory markers have 
been shown to have direct effects on vascular responses suggesting they can impair blood 
flow as soon as they appear.  As discussed, both TNFα and iNOS have both been shown to 
alter vascular signalling [72, 126-128, 143, 160, 161].  Acute infusion of TNFα has been 
shown to directly impair insulin-mediated blood flow responses by preventing the 
recruitment of the microvasculature [126, 143], whilst excessive nitric oxide production from 
iNOS has been shown to interfere with the highly coordinated actions of the vasculature [72, 
127, 161].  Preliminary studies conducted by Bussey (2011, University of Tasmania, PhD 
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thesis) also provide evidence for impaired muscle vascular responses after 4 weeks of high fat 
feeding that could be restored by iNOS-specific inhibition, suggesting that even at this early 
time point iNOS over-expression potentially impairs vascular reactivity in skeletal muscle.  
However despite this a direct link between the induction of microvascular impairment and the 
induction of diet-induced inflammation has not yet been clearly identified.   
 
As obesity and inflammation have been closely linked within the literature, it is of no surprise 
that a key site of inflammatory induction is within the adipose tissue itself.  This is because in 
addition to its role in lipid storage, the adipose tissue is highly active endocrine organ that 
secretes a number of hormones and adipokines [163-165].   However despite the current 
research within the literature, the mechanisms surrounding obesity-induced inflammation still 
remain elusive.  It has been proposed that the adipose tissue can undergo unhealthy or 
unhealthy expansion in response to provide adequate nutrient storage, however the 
mechanisms surrounding whether healthy or unhealthy expansion occurs is still not fully 
understood [166].  In healthy conditions the adipose tissue undergoes hypertrophy and 
hyperplasia to accommodate additional lipid storage.  In this state, adipose tissue expansion is 
associated with increased angiogenesis to supply adequate oxygen and nutrients to the 
expanding tissue.  It is hypothesised that at times when excessive lipid storage is needed, 
such as during high fat feeding or obesity, adipose tissue expansion occurs at a much higher 
rate.  This rapid expansion of the adipose tissue results in excessive adipocyte hypertrophy.  
It has been found that the additional remodelling that occurs during healthy expansion, such 
as the development of new adipocyte cells and vascular growth, either does not occur during 
this rapid expansion process or it occurs at a much lower rate [165, 166].  Due to their large 
size and inadequate oxygen availability, poorly oxygenated adipocytes can become hypoxic 
within the tissue.  This triggers the increased expression of Hypoxic Inducible Factor 1α 
(HIF-1α) to the hypoxic sites [167-169].  HIF-1α has been identified as an early initiator of 
inflammatory responses and can signal for the induction of macrophages and the proliferation 
of inflammation factors in the tissue.  Very poorly oxygenated adipocytes may become 
necrotic which also induces increased inflammatory responses and macrophages locally 
within the tissue [166, 170, 171].  Therefore unhealthy expansion and the development of 
hypoxia within the adipose tissue is a possible factor underlying the induction of obesity-
induced inflammation in insulin resistant conditions.  However further studies are required to 
confirm this proposed mechanism.                     
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1.4  Summary of research aims 
A key unanswered question regarding obesity and insulin resistance is the development of 
inflammation in this state and whether obesity-induced inflammation contributes towards the 
development of both muscle and vascular insulin resistance.  A number of inflammatory 
molecules, such as TNFα and iNOS, have been shown to alter and impair insulin-mediated 
responses within both the muscle and vasculature, however currently the mechanisms 
regulating the induction of inflammatory responses within obesity are still not understood.  
The vast majority of inflammatory studies in regards to diet induced obesity have primarily 
been performed in mouse models, and similar studies in rats are considerably outnumbered.  
Therefore investigation of diet-induced obesity on inflammation and insulin resistance in rats 
will allow, not only for the investigation of inflammation on physiological responses such as 
blood flow, but also contribute to the current literature by providing further information as to 
its presence in rats for comparison. Therefore, this project hypothesises that inflammation is a 
key contributor to the development of both microvascular and skeletal muscle insulin 
resistance in diet-induced obesity in rats.  Therefore, the aim of this thesis was to investigate 
the influence of obesogenic diets on the induction of adipose tissue inflammation, and the 
contribution of inflammation to obesity-induced muscle and vascular insulin resistance.   
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CHAPTER 2 
 
 
 
MATERIALS AND METHODS 
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2.1 Animals   
Male Sprague Dawley rats, approximately 4 weeks of age, were obtained from the University 
of Tasmania Central Animal Facility.  All animals were housed in temperature and light 
controlled conditions (21ºC ± 1ºC) with a 12 hour light/dark cycle.  Animals were provided 
with free access to water and commercial semi purified diets.  Details of the various dietary 
interventions are provided in each chapter accordingly.   
All experiments and procedures were approved by the University of Tasmania Animal Ethics 
committee and undertaken in accordance to the Australian Code of Practice for the Care and 
Use of Animals for Scientific Purposes (7
th
 Edition, 2004).   
 
 
2.2 Anaesthetised Rat Experiments 
 
2.2.1 Surgical Procedure   
Rats were anaesthetised with an intraperitoneal injection of sodium pentobarbital (50mg/kg 
body weight).  A tracheostomy tube was surgically inserted to allow for spontaneous 
breathing during the experiment.  Cannulas were inserted into both jugular veins to allow for 
intravenous infusion.  Another cannula was inserted into the carotid artery and connected to a 
pressure transducer (Transpac IV, Abbott Critical Systems) to allow for the measurement of 
blood pressure.  Arterial blood sampling was also performed through the carotid cannula line.  
The femoral blood vessels of one hindlimb were exposed and the femoral artery was carefully 
separated from the femoral vein and nerve.  The epigastric vessel was ligated and a flow 
probe (0.5 mm VB series, Transonic Systems) was positioned around the femoral artery to 
allow for the measurement of total femoral blood flow.  Both the vessels and flow probe were 
covered in lubricating jelly (Mohawk Medical Supply, Utica).  The probe was connected to a 
flow meter (model T106 ultrasonic volume flow meter, Transonic Systems) which was 
connected to an IBM-compatible computer.  Figure 2.1 outlines the surgical procedure 
performed.   
Blood pressure, heart rate, and femoral artery blood flow were measured continuously using 
WINDAQ data acquisition software (DATAQ Instruments).  Anaesthesia was maintained by 
the continuous infusion of aqueous sodium pentobarbital (0.6mg/min/kg body weight) via the 
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jugular vein.  Body temperature of the rat was maintained at 37ºC using a heated pad and 
heating lamp.  Completion of the surgical procedure was followed by a 60 minute 
equilibration period to allow for blood pressure to stabilise before a 2 hour insulin clamp was 
performed.   
 
 
2.2.2 Muscle Glucose Uptake   
Skeletal muscle glucose uptake was measured by the uptake of 2-deoxy-D-[1-
14
C] glucose (2-
DG, 0.1 mCi/mL, Perkin Elmer) as previously described [172].  In brief, 45 minutes prior to 
the end of the hyperinsulinemic euglycaemic clamp procedure a 200µL bolus of 2-DG was 
given (20µCi).  Arterial plasma samples (25µL) were collected 5, 10, 15, 30, and 45 minutes 
after the 2-DG bolus to assess plasma clearance of 2-DG.  At the end of the clamp procedure 
calf muscle was excised, immediately freeze clamped in liquid nitrogen, and kept at -80ºC 
until required.  The frozen muscle was ground into a fine powder under liquid nitrogen and 
approximately 100mg of powdered muscle was homogenised with 1.5mL of distilled water 
using a Heidolph silent crusher.  The homogenate was centrifuged at 13,000 rpm at 4ºC for 
10 minutes and 1mL of supernatant was assessed for free and phosphorylated 2-DG using an 
anion exchange column (AG-1X8, Bio-Rad Laboratories).  Biodegradable counting 
scintillant (Amersham) was combined with each radioactive sample and radioactivity was 
measured using a scintillation counter (Perkin Elmer).  From this measurement and the 
disappearance of 2-DG in plasma, the rate of glucose uptake by the skeletal muscle (R’g), 
was calculated as described by others [172] and expressed as µg/g/min.   
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Figure 2.1 – Diagram of surgical procedure for anaesthetised rat experiments.   
Following anaesthesia a tracheostomy tube was inserted and both jugular veins and the carotid 
artery were cannulated to allow for monitoring of blood pressure and heart rate, measurement 
of arterial blood glucose concentrations, and the intravenous infusion of anaesthetic, insulin, 
and glucose for hyperinsulinemic euglycaemic clamp experiments.  The femoral artery of one 
hindlimb was also exposed and carefully separated and a transonic flow probe was positioned 
around the isolated artery to measure femoral blood flow.      
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2.2.3 Skeletal muscle microvascular perfusion   
Microvascular perfusion within skeletal muscle was measured by the metabolism of 
exogenously infused 1-methyl xanthine (1-MX) as described elsewhere [23, 86].  In brief, a 
bolus of allopurinol (10µmol/kg, Sigma Aldrich) was given 5 minutes before 1-MX infusion 
in order to partially inhibit xanthine oxidase activity and ensure a constant saturating arterial 
level of 1-MX.  Infusion of 1-MX (0.4mg/min/kg body weight) occurred for the final 60 
minutes of the clamp procedure.  At the end of the experiment 100µL of arterial plasma was 
added to 20µL of perchloric acid (2M) to precipitate the proteins.  Hind-leg venous plasma 
was obtained from the femoral vein and 100µL was mixed with 20µL perchloric acid (2M).  
Samples were centrifuged for 10 minutes and the supernatant was assessed for 1-MX and 
oxypurinol concentration using reverse-phase high-performance liquid chromatography as 
previously described [23, 173].  1-MX metabolism (nmol/min) was calculated from the 
difference of arteriovenous plasma 1-MX levels multiplied by femoral blood flow.   
 
 
2.3 Gene Expression Experiments 
 
2.3.1 Tissue Sample Preparations   
Gastrocnemius muscle and epididymal fat pad samples were taken from anaesthetised 
Sprague Dawley rats at the end of hyperinsulinemic euglycaemic clamps.  Tissue samples 
were freeze clamped in liquid nitrogen and stored at -80ºC until required.  Frozen tissue 
samples were ground into a fine powder in liquid nitrogen and stored at -80ºC until required.   
 
2.3.2 RNA Extraction   
Total RNA was extracted from ground tissue samples using the Tri Reagent method (Sigma 
Aldrich).  Approximately 100mg of ground skeletal muscle and 150-200mg of ground 
adipose tissue was used for each extraction.  The RNA pellet was resuspended in 10-20µL of 
PCR-grade water (RNAse and DNAse free) (Bioline or Qiagen) and RNA concentration was 
quantified by measuring spectrophotometer absorbance at 260nm.  RNA quality was also 
assessed and an A260/280 ratio value of ‘2’ was obtained for all RNA used in the following 
experiments.  RNA was stored at -80ºC until required if use was not immediate.   
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2.3.3 Polymerase Chain Reaction (PCR) 
2.3.3.1 Quantitative PCR   
RNA extracted from ground tissue samples was reverse transcribed to obtain complementary 
DNA (cDNA) strand.  Total RNA was diluted to a concentration of 1µg per reaction before 
being reverse transcribed and amplified per set of primers (GeneWorks Australia) using 
SuperScript III (Invitrogen).  Reverse transcription was performed on a T100 Thermal Cycler 
(BioRad) and conditions consisted of 50ºC for 60 minutes, 70ºC for 15 minutes, and then 
sample temperature reduced to 4ºC.  Samples were held at 4ºC until required.   
Real time PCR (qPCR) was performed using SYBR Green (Qiagen) on cDNA obtained 
through reverse transcription.  Incubation conditions for qPCR were are follows:  95 ºC for 
15 minutes for initial denaturation followed by 35 cycles of 95 ºC for 30 seconds, 60 ºC for 
60 seconds, and 72 ºC for 120 seconds followed by an extension of 81 ºC for 15 seconds to 
acquire fluorescence reading.  All samples were run on a Rotor-gene 6000 real time PCR 
machine for analysis of gene expression (Corbett Research).  Ct vales were obtained with a 
fluorescence threshold at 0.05 for all samples.  A melt curve of fluorescence versus 
temperature (ºC) was performed to check for primer-dimer formation within the samples.   
Primer sequences for each gene investigated are provided in Table 2.1.  
 
Table 2.1 – Primer sequences for measurement of inflammatory gene expression by q-PCR 
Above table shows both forward and reverse primer sequences used to obtain cDNA and measure 
gene expression of the inflammatory and macrophage markers iNOS, TNFα, EMR1, and MCP-1 in 
the adipose tissue and skeletal muscle of rats by reverse transcription and real time PCR (qPCR).  
Ribosomal protein S9 was used as a housekeeper gene.  Primers were sourced from GeneWorks, 
Australia. 
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2.3.4  Calculation of Relative Gene Expression 
Quantification of mRNA expression for each gene was essentially as described previously 
[174].  Briefly, standard curves for each inflammatory marker and housekeeper gene were 
performed by purifying and cleaning PCR product for each marker, establishing a relative 
concentration of the cleaned product, and producing a serial dilution.  The qPCR protocol 
was re-performed on the serial dilution of each marker.  The standard curve was created by 
plotting the Ct values against log2 copies by linear regression and the following calculation 
(y=ax+b) could be determined.  The coefficient of determination (R
2
) of the line, and thus the 
standard curve, was used to calculate cDNA copy number in the original reverse transcription 
reaction, which is proportional to the initial mRNA concentration.  This takes into account 
small differences in PCR amplification efficiency (ideally with a slope of 1 on the standard 
curve) that delta Ct comparisons used in some studies do not take into account. Gene 
expression was thus determined  from the log of cDNA copy number determined from the Ct 
versus log copy number standard curve for each gene, and the absolute copy number 
expressed as a ratio to housekeeping gene (ribosomal S9 mRNA) copy number for each 
sample.  This allowed to correct for differences in mRNA input into the PCR reactions. Note 
that this method preserves information about mRNA absolute copy number so that data from 
different PCR runs can be compared, whereas delta Ct comparisons must include samples 
from different experiments in a single run or establish that amplification efficiency has not 
changed between runs. 
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3.1 Introduction 
 
Dietary interventions in animal models have been used extensively to study a range of health 
outcomes.  High fat feeding has proven to be an effective method to induce an obese 
phenotype in animal models and has been extensively used for research purposes to 
investigate diet-induced obesity and associated health implications such as insulin resistance 
and Type 2 Diabetes [26, 86, 138, 175].  Use of high fat diets mimics unhealthy eating habits 
that are prevalent in humans, with poor dietary intake being a leading cause of obesity and 
associated metabolic impairments.  These animal models allow for a detailed examination of 
these impairments in order to gain further understanding into the mechanisms underlying 
their induction in addition to potential treatment avenues [71, 86, 176-178].  The vast 
majority of obesogenic diets are primarily based on a high fat content with most containing 
levels ranging from 20-60% of calories derived from fat [26, 86, 177, 179, 180].  Many 
variations of high fat dietary interventions exist, including the amount of fat content within 
the diet [86, 117, 138, 180], types of fat used [179, 181, 182], and duration of diet treatment 
[26, 117].  Some other dietary factors such as high sugar [183] or salt [184] have also been 
investigated in conjunction with high fat treatment.   
 
High fat diets have been shown to be effective at producing significant obesity with 
associated insulin resistance after only short-term intervention in rodents.  Approximately 4 
weeks of high fat dietary intervention has been shown to induce significant obesity with 
associated insulin resistance in rats [86, 176, 180] in addition to also impairing microvascular 
recruitment and blood flow within skeletal muscle [86, 138].  Increased adiposity, impaired 
glucose tolerance, and systemic insulin resistance has been shown to develop after 3 days of 
high fat feeding in mice [26].  A number of inflammatory and macrophage markers are found 
to be significantly expressed within the adipose tissue in mice at this time-point, however the 
inflammatory response was shown to progressively worsen as high fat feeding extended long-
term [26].     
  
It has been widely reported that inflammation is associated with obese and insulin resistant 
conditions [18, 19, 26, 27, 123, 124, 185] however in spite of its strong association within the 
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literature, the rate by which inflammation develops in diet-induced obesity, and whether 
inflammation has the potential to impair microvascular and insulin-mediated responses at 
early stages of insulin resistance has not been fully established.  A number of inflammatory 
markers have been highlighted as having a potential influence by impairing insulin sensitivity 
and vascular responses [122, 126, 127, 129].  Impaired insulin-mediated microvascular 
responses have been shown to be an early defect observed in insulin resistance as this altered 
blood flow response negatively impacts the delivery and uptake of glucose by the skeletal 
muscle [23, 32, 86, 138].  The vasculature may therefore be a critical site that inflammatory 
cytokines act at, and thus contribute to the development of whole body insulin resistance.     
 
It has been shown that TNFα in rats can alter vascular responses and glucose uptake within 
insulin sensitive tissue such as skeletal muscle.  Acute administration of TNFα in rats results 
in a significant inhibitory effect on insulin-mediated haemodynamic responses by blocking 
blood flow and capillary recruitment, resulting in an insulin resistant state with decreased 
glucose uptake by skeletal muscle and decreased whole body insulin sensitivity [126, 143].  
There is also evidence that iNOS, the inducible isoform of nitric oxide synthase [108, 186], 
could be a contributing factor towards dysfunction in obese and insulin resistant states as 
shown in mouse studies [71, 127, 129].  This is believed to occur predominately due to 
increased vasoconstrictor responses of the vascular endothelium in order to compensate for 
the excessive production of nitric oxide when iNOS is induced which stimulated vasodilation 
of the vascular endothelium [127, 128, 161].  This results in significant endothelial 
dysfunction and alteration of vascular responses.  Studies have also shown that iNOS 
knockout mice are protected against high fat diet-induced insulin resistance [71, 129].  Obese 
iNOS knockout mice display improved glucose tolerance and normal insulin sensitivity 
compared to obese wild-type mice after high fat feeding [129].  Whilst obese wild-type mice 
showed impaired activation of insulin signalling intermediates PI3K and Akt in muscle, 
obese iNOS knockout mice did not show these same defects [129].  Use of the nitric oxide 
inhibitor L-NAME has also shown similar metabolic improvements in mice [71, 129].  
Preliminary studies conducted by Bussey (2011, University of Tasmania, PhD thesis) 
reported that rats fed a high fat diet for 4 weeks exhibited impaired vascular responsiveness 
to endothelin-1 in a perfused hindlimb model, and vascular responsiveness was restored to 
that seen in control diet-fed animals by the use of iNOS inhibitor 1400W, or the broader NOS 
inhibitor L-NAME.  These findings suggested that even at early time points iNOS 
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overexpression potentially impairs vascular reactivity in skeletal muscle.  The findings from 
these studies provide strong evidence that iNOS could play an important role in the 
development of insulin resistance.       
 
Other cytokines such as MCP-1 are also strongly associated with obese conditions.  MCP-1 
strongly promotes and recruits macrophages to infiltrate into tissues of high fat fed mice, with 
its expression found to be significantly increased in obese adipose tissue [122].  These 
recruited macrophages may secrete a variety of cytokines and chemokines which can then 
promote an inflammatory response locally within the tissue [122].  And as mentioned above, 
a number of inflammatory markers have shown to have the ability to directly impair insulin’s 
actions [126, 129].  Treatment of cultured human skeletal muscle cells with MCP-1 has 
shown impairment to insulin signalling and significantly reduced glucose uptake in the 
mycocytes [146].  Both insulin resistance and accumulation of macrophage markers within 
the adipose tissue were found to be extensively reduced in MCP-1 knockout mice compared 
to wild-type controls after high fat feeding [122].  These results suggest that MCP-1 may also 
have the potential to directly contribute towards the pathogenesis of insulin resistance in 
addition to its chemoattractant role in recruiting macrophages to initiate an inflammatory 
response.   
 
Much research into the relationship between obesity and inflammation has been conducted in 
mouse models [26, 27, 123, 124, 177, 187], with similar studies in rats being severely 
outnumbered [185, 188].  The reasons for why mice are favoured over rats for inflammatory 
studies have not been greatly discussed within the literature.  Mice, however, may potentially 
be preferred due to their small size and ease for genetic manipulation [26, 127, 129].  Many 
of the studies investigating inflammation and obesity have been conducted in specific 
knockout models [26, 127, 129], genetic models of obesity such as (ob/ob) mice [154, 189], 
as well as models which use chemicals to induce a diabetic and insulin resistant state such as 
streptozotocin [127, 190].  Although many studies have examined inflammatory expression 
in response to diet-induced obesity in mice [26, 71, 185, 191], the direct impact obesity-
associated inflammation may have at impairing insulin-mediated responses have not been 
well established in rat models.  Rats provide better models for studying larger system 
physiology due to both their larger size which enhances them as a disease model, and their 
31 
 
suitability for studying human diseases due to similar physiology [192].  They have been 
shown to be especially good models of cardiovascular disease, hypertension, and stroke [162, 
192, 193].  These conditions are not only regularly associated with obesity, but have also 
been shown to have increased inflammatory responses [29, 100].   
 
Because of this it is important to investigate inflammatory responses in rats to enhance and 
extend knowledge from mouse studies, but to also understand the relationship inflammation 
may have on larger physiological systems such as vascular responses and skeletal muscle 
insulin resistance.  And while the majority of studies of obesity-induced inflammation have 
been reported from mice, the findings of Bussey (2011, Univeristy of Tasmania, PhD thesis) 
that iNOS overexpression potentially impairing vascular reactivity in skeletal muscle, 
suggested that a similar inflammatory process may occur in high fat-fed rats.  As mentioned, 
mice are not amenable to study larger system physiology and the eventual measurement of 
inflammation-induced microvascular impairment for technical reasons. Currently contrast-
enhanced ultrasound measurement of microvascular flow has not been performed for mice, 
and although a desirable objective, this would require considerable experimentation to perfect 
for mice, limiting the current thesis to the study of the microvascular effects of inflammation 
in rats, for which CEU has been extensively published [85, 87, 140, 194-197].   
 
The fact that pro-inflammatory markers have been shown to impact haemodynamic responses 
and glucose uptake within skeletal muscle provides a preliminary theory as to how 
inflammation may contribute to altered metabolic responses seen in insulin resistance [126, 
127, 129, 143].  This study aims to investigate whether inflammation occurs after a 4 week 
high fat dietary intervention in rats which provides an obese model with significantly 
impaired insulin-mediated responses such as stunted glucose uptake within skeletal muscle 
and whole body insulin resistance.    
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3.2 Materials and Methods 
 
3.2.1 Animals 
Male Sprague Dawley rats approximately 4 weeks of age were obtained from the University 
of Tasmania Central Animal Facility.  On arrival rats were split into two groups with one 
group provided with a control diet (11% calories derived from fat), and the other a high fat 
(41% calories derived from fat) diet ad libtitum for 4 weeks.  Drinking water was provided ad 
libitum. 
Macronutrient composition of these diets are shown in Table 3.1.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1 – Macronutrient composition of control and high fat diets 
expressed as % total weight 
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3.2.2 Protocol 
Surgery was performed as outlined previously in Chapter 2, section 2.2.1.  Following the 
surgical procedure mean arterial blood pressure was allowed to stabilise for 1 hour, after 
which a 2 hour infusion of insulin (10 mU/min/kg) was initiated.  A 30% glucose solution 
(wt./vol.) was infused at a variable rate to maintain basal blood glucose concentrations over 
the course of the experiment.  Arterial blood glucose levels were measured every 10 minutes 
for the first hour, and every 15 minutes in the second hour of the clamp procedure using a 
glucose analyser (YSI 2300).  Measurement of the blood glucose levels allowed the glucose 
infusion rate (GIR) to be adjusted accordingly to maintain basal levels.  Figure 3.1 provides a 
detailed experimental protocol.  Muscle glucose uptake and skeletal muscle microvascular 
perfusion were assessed as outlined in Chapter 2, section 2.2.2.     
 
 
 
 
 
 
Figure 3.1 – Experimental protocol of hyperinsulinemic euglycaemic clamp procedure 
in vivo.  Following surgical preparation a 60 minute equilibration period was allowed for 
stabilisation of blood pressure.  Following this a continuous infusion of insulin (10 
mU/min/kg) was commenced and continued for 120 minutes.  A 30% (wt/vol) glucose 
infusion was initiated shortly after the commencement of the insulin infusion in order to 
maintain basal blood glucose levels.  This was assessed by arterial blood sampling ( ).  At 
55 minutes a bolus of allopurinol (10µmol/kg) was given before an infusion of 1-
methylxanthine (1-MX) was started at 60 minutes.  At 75 minutes a bolus of 2-DG (20 µCi) 
was administered and radioactive plasma samples ( ) were collected at 80, 85, 90, 105, 
and 120 minutes to determine the clearance of plasma 2-DG.  At the conclusion of the 
experiment arterial plasma samples were collected for the determination of hindlimb glucose 
uptake ( ).  After samples were taken at 120 minutes animals were sacrificed and calf and 
epididymal fat pads were immediately excised, weighed (epididymal fat pads only) and 
freeze clamped in liquid nitrogen and stored at -80ºC.   
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3.2.3 Gene expression  
Expression of inflammatory markers was performed by two step reverse transcription real-
time PCR (RT-q-PCR).  RNA was first extracted from skeletal muscle and adipose tissue 
samples and reverse transcribed using SuperScript III (Invitrogen) to obtain cDNA as 
described previously in Chapter 2, section 2.3.  Real time PCR (qPCR) was performed using 
SYBR Green (Qiagen) to amplify the target DNA sequence and quantify gene expression of 
the chosen inflammatory markers (iNOS, TNFα, MCP-1, and EMR1) as described in Chapter 
2, section 2.3.  Inflammatory gene expression is shown as the relative expression to the 
housekeeper S9.  The gene expression measurements were performed in a subset of study 
animals (5-6 per group) and powered to detect changes of 50% or greater.   
 
 
3.2.4 Data and statistics 
Data is present as means ± SEM and statistical analysis was performed using SigmaStat 
(Systat Software Inc).  Comparisons between groups were made using un-paired Student’s t-
test and two-way ANOVA.  Comparison of time-series measurements in each group was 
performed by two-way repeated measures ANOVA.  When a significant difference of p<0.05 
was detected, pairwise comparisons by Student-Newman-Keuls test was used to assess 
treatment differences.   
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3.3 Results   
 
Four weeks of high fat feeding produced notable obesity with epididymal fat pad weight 
significantly heavier in high fat fed rats compared to controls (Figure 3.2, B).  This adiposity 
was associated with significantly increased body weight of high fat fed rats (Figure 3.2, A).   
Whole body insulin sensitivity was impaired in high fat fed rats compared to controls after 4 
weeks of dietary intervention with high fat feeding.  GIR during hyperinsulinemic 
euglycaemic clamps was significantly impaired in high fat fed animals compared to controls 
(Figure 3.3).  Insulin stimulated significant glucose uptake in the skeletal muscle of both 
control and high fat fed rats compared to saline infusion (Table 3.2, Figure 3.4, A).  However 
comparison of diet treatment between insulin clamps showed high fat fed rats to have a 
significantly blunted glucose uptake compared to control animals.  Insulin also significantly 
increased microvascular perfusion within the skeletal muscle of control-fed animals but not in 
high fat fed rats (Figure 3.4, B).    
 The expression of pro-inflammatory and macrophage markers within the adipose tissue of 
high fat fed rats were found to be no different to control-fed animals after 4 weeks (Table 
3.2).  There were no significant correlations between inflammatory gene expression levels 
and GIR (data not shown).   
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Figure 3.2 – Effect of 4 weeks high fat feeding (41% fat) on (A) body weight 
and (B) adiposity in control () and high fat fed () Sprague Dawley rats.  
Epididymal fat pads were excised and weighed immediately after removal.  Mean 
wet weight as percentage of body weight is shown for each group ± SEM for n = 
25-27 rats.  ** = p < 0.01 and *** = p < 0.001 indicate significant difference by 
Student’s t-test. 
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Figure 3.3 – Effect of a 41% high fat diet on whole body insulin sensitivity of control 
() and high fat fed rats () during hyperinsulinemic euglycaemic clamp.  Data shows 
means ± SEM for n = 14-17 rats in each group. * = p<0.05 indicated significant difference 
between control and high fat diet groups two-way repeated measures ANOVA.   
Metabolic parameters were measured by performing 10 mU hyperinsulinemic euglycaemic 
clamps in anaesthetised animals, with glucose infusion rate reflecting whole body insulin 
sensitivity.  Muscle glucose uptake was calculated by 2-deoxy-D-Glucose uptake during 
final 45 minutes of clamp procedure.  Data shows means ± SEM for n = 14-17 rats in each 
group. * = p<0.05 indicated significant difference between control and high fat diet groups 
for GIR measurement by two-way repeated measures ANOVA.   
Table 3.2 - Effect of a 41% high fat diet on metabolic responses 
and insulin sensitivity of control and high fat fed rats. 
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Figure 3.4 – Effect of a 41% fat diet on (A) muscle glucose uptake and (B) 
microvascular perfusion in the skeletal muscle control () and high fat fed rats () 
with or without insulin infusion during hyperinsulinemic euglycaemic clamp 
procedure.  Muscle glucose uptake was calculated by 2-deoxy-D-Glucose uptake during 
final 45 minutes of clamp procedure.  Microvascular perfusion within skeletal muscle was 
assessed by the metabolism of 1-MX.  Data shows means ± SEM for n = 8-17 rats in each 
group.  ** = p<0.01, *** = p<0.001 indicates significant difference within respective diet 
treatments; ## = p<0.01, ### = p<0.001 indicates significant difference from Control + Ins 
group by two-way ANOVA.    
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Table shows relative expression of inflammatory marker mRNA ratio to the 
housekeeper S9 in Sprague Dawley rats fed a control or 41% high fat diet for 4 weeks.  
Inflammatory gene expression was not found to be up-regulated in the visceral adipose 
tissue of high fat fed rats compared to controls.  Data shows means ± SEM for n = 5-6 
rats in each group.  Statistical analysis was performed by Student’s t-test.   
Table 3.3 – Comparison of inflammatory gene expression in visceral adipose 
tissue of control and high fat diet-fed rats after 4 weeks 
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3.4 Discussion 
 
As expected and previously shown by other studies, 4 weeks of high fat feeding was effective 
at inducing an obese phenotype with associated insulin resistance in rats [86, 180, 198].  Use 
of a 41% fat diet produced significant adiposity in rats after only 4 weeks resulting in these 
animals being much heavier than matched controls (Figure 3.2).  Whole body insulin 
sensitivity, as reflected by GIR, as well as glucose uptake and microvascular perfusion within 
skeletal muscle were all significantly impaired in rats fed this high fat diet compared to 
control-fed animals (Figure 3.3 & 3.4, Table 3.2).  These results confirm high fat feeding to 
be an effective tool to study obesity and its associated metabolic complications.   
 
However despite high fat feeding resulting in significant obesity and adipose tissue 
accumulation, expression of inflammatory and macrophage markers were not found to be 
significantly elevated within the adipose tissue of high fat fed rats compared to controls 
(Table 3.3).  Only a subset of the cohort was examined in the inflammatory gene expression 
studies which may weaken the results, however these experiments were powered to detect a 
change of 50% or greater.  Still the lack of any pro-inflammatory respose was surprising due 
to obesity-associated inflammation being regularly reported within the literature in other 
animal models with inflammation highlighted as an important factor in the development of 
obesity-associated insulin resistance [18, 27, 120, 199].  Although these rats showed 
significant adipose tissue accumulation, it is possible that a greater degree of obesity is 
required to initiate a significant pro-inflammatory response within the adipose tissue.  Mice 
fed a high fat diet show excessive obesity with adipose tissue often reported to be two to 
three times greater than that of matched control animals after short-term feeding [26, 72, 200, 
201].  Although our rats obtained significant adiposity with this 41% fat diet (Figure 3.2, B), 
the epididymal fat pad weight of rats on this diet showed approximately a 50% increase in 
adiposity compared to controls.  Therefore the degree of obesity seen in our rats is not quite 
as large as that obtained in mice [27, 200, 202].   
 
It is important to highlight that many high fat fed mouse studies use diets with a fat content 
where approximately 60% of the calories are derived from fat [26, 117, 120, 177, 201, 203].  
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In contrast the calories derived from fat in the diet used in this study equate to 41% (Table 
3.1).  Mice on this diet have been shown to produce significant adiposity that is 
approximately 3 times greater than that of control animals after only 2 weeks of dietary 
intervention [26].  Long-term studies in mice with this 60% high fat diet has also found 
significant inflammation within the liver, skeletal muscle, and adipose tissue after 16 weeks, 
however minor inflammation was measured in the adipose tissue within one week of high fat 
diet [26].     
 
In conclusion, although a 41% high fat diet was shown to be successful at producing 
significant adiposity and insulin resistance in rats in did not induce a significant inflammatory 
response within the adipose tissue.  It appears that obesity-associated inflammation may 
require a certain degree of obesity in order for an inflammatory response to be induced within 
the tissue.  Increasing the dietary fat content should result in excessive lipid accumulation and 
added stress within the adipose tissue, which should result in the induction of macrophages 
and pro-inflammatory factors within the tissue.  Long-term high fat feeding should also 
establish a chronic degree of obesity and insulin resistance and provide a more detailed 
analysis of the progression and development of obesity in rats, allowing for a more thorough 
relationship between obesity and inflammation over time.     
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CHAPTER 4 
 
 
 
EFFECT OF FAT CONTENT AND 
DIET DURATION ON OBESITY, 
INSULIN RESISTANCE, AND 
INFLAMMATION 
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4.1 Introduction 
 
As previously discussed in Chapters 1 and 3, high fat feeding has been used to study diet-
induced obesity and its associated health implications such as insulin resistance and vascular 
dysfunction in animal models.  High fat feeding has been widely reported as an effective 
method of increasing adiposity and inducing insulin resistance in rodents [26, 86, 202-205].  
Although used widely, the exact composition of high fat diets used varies between studies 
[86, 138, 179, 180, 206].  Many obesogenic studies have favoured diets with a much higher 
fat content (60% calories from fat) than that used in Chapter 3 (41% calories derived from 
fat), despite diets with a lower fat content having been shown to be effective at inducing an 
obese and insulin resistant phenotype [138, 180, 182].  The majority of obesogenic studies 
report high fat diets have employed approximately 60% of the calories being derived from fat 
[26, 86, 120, 130, 176, 177, 198, 201, 203].  These higher fat diets have been shown to 
produce excessive obesity in mice with the adipose tissue of animals on this type of diet 
reported to be double or more of that measured in matched controls [26, 72, 200, 201, 207, 
208].  The adiposity in high fat-fed rats appears more variable and may require much longer 
interventions to reach similar degrees of obesity to those seen in mice [86, 176, 198, 209-
211].  Therefore it is important to directly investigate the use of a higher fat diet on adiposity 
in rats, and determine whether increased fat content, or a longer diet duration, results in a 
greater degree of adiposity (and inflammation) than that obtained previously in Chapter 3.   
 
Both dietary fat content and diet duration could be important factors for the development of 
obesity and obesity-induced inflammation in rats.  Long-term studies within the literature 
have regularly been reported as 8-16 weeks of intervention treatment, with some studies 
extending as far as 20 weeks or above [26, 117, 120, 191, 198, 202, 206, 212].  Long-term 
dietary interventions have shown that high fat feeding can produce significant obesity in 
animals, with adipose tissue accumulating to two to three times higher than that of age-
matched controls.  This is accompanied by significant insulin resistance and impaired glucose 
tolerance [26, 198, 202, 203].  These impairments have been shown to be induced in earlier 
stages of high fat feeding, however a number of long-term studies have found that they can 
become more severe as dietary intervention continues [26, 203].  The high fat diets used for 
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the majority of these long-term interventions have ranged between 45 – 60% energy from fat 
[26, 120, 191, 198, 202, 210].   
 
As an inflammatory response was not seen in the adipose tissue of 4 week high fat fed rats 
(41% calories from fat, Chapter 3), using both a diet with a higher fat content (60% calories 
from fat) for 4 weeks and extending high fat feeding for a longer intervention (12 weeks) 
should allow for the development of significant obesity which may be more likely to induce 
an inflammatory response within the tissue.  This dietary intervention should allow the degree 
of obesity required for significant inflammatory expression in high fat fed rats to be 
determined which will potentially provide further insight into the mechanisms required for 
the induction of inflammation.  Use of a diet with a higher fat content requires greater lipid 
accumulation within the adipose tissue, as shown by the adipose tissue of animals fed this 
higher fat diet being double or more in weight compared to control animals [26, 86, 176, 
201].  High fat fed mice have even shown significant adiposity as soon as 3 days after the 
commencement of a high fat diet [26].  Therefore this excess lipid accumulation places added 
stress upon the adipose tissue to respond and accommodate excessive lipid storage, even in a 
short period of time.  The adipose tissue must undergo remodelling, often via hypertrophy or 
hyperplasia, in order to increase the storage capacity of the tissue in response to this demand 
[166].  This remodelling and additional stress may promote factors such as macrophages to 
migrate and proliferate within the tissue to induce an inflammatory response through the 
secretion of cytokines [122, 163, 166, 213].  Studies which have examined obesity-associated 
inflammation in mice record excessive adipose tissue obesity which is found to associated 
with the increased expression of a number of inflammatory factors within the tissue [26, 27, 
123].  Inflammatory gene expression of certain factors such as TNFα, MCP-1, and EMR1 
have been show to be induced within the adipose tissue as quickly as 3 to 7 days after high fat 
feeding, however a stronger and more significant inflammatory expression is observed as 
high fat feeding progresses long-term [26].  The majority of studies investigating obesity-
associated inflammation have been conducted in mouse models, however very little is known 
about this response in rats.   
 
A detailed time-course study investigating the differences between short and long-term high 
fat feeding with inflammation was conducted by Lee et al. in mice [26].  The expression of a 
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number of inflammatory markers, including TNFα, iNOS, MCP-1, and EMR1, was examined 
in the liver, skeletal muscle, and adipose tissue of mice that had undergone short-term (1, 3, 
and 7 days) and long-term (16 weeks) high fat feeding interventions.  Although a few of these 
inflammatory markers showed significant increases at certain time-points during the short 
interventions, long-term high fat feeding produced a much more significant expression of all 
inflammatory genes in all tissue samples analysed.  This expression ranged from 5 to 40 
times that measured in controls.  The study by Lee et al. [26] showed a clear systemic 
inflammatory response with long-term high fat feeding, however significant inflammation 
only occurred much later when obesity was well established in these animals.  Despite this, 
the increases in inflammatory markers observed in both the adipose tissue and skeletal 
muscle of 16 week high fat fed mice [26] suggests that a similar systemic inflammatory 
response is possible in rats with long-term high fat feeding.  However, comparable studies of 
obesity-associated inflammation, as that done by Lee et al. [26] in mice, have not been 
conducted in rats.   
 
Therefore this study aims to investigate the expression of obesity-associated inflammation 
generated through dietary intervention with a significantly high fat diet (60% calories derived 
from fat) and longer exposure to the diet in rats.  The use of both a higher fat diet and longer 
dietary intervention will allow for examination into the degree of adiposity required to induce 
an inflammatory response, and whether inflammatory factors generated from diet-induced 
obesity can further impair insulin sensitivity of high fat fed animals.   
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4.2 Materials and Methods   
 
4.2.1 Animals 
Male Sprague Dawley rats approximately 4 weeks of age were obtained from the University 
of Tasmania Central Animal Facility.  On arrival rats were split into equal groups and 
provided with either a control (11% calories derived from fat) or high fat diet (58% calories 
derived from fat) ad lititum for 1, 4, 8 and 12 weeks.  Macronutrient breakdown of these diets 
is shown in Table 4.1.  Drinking water was provided ad libitum.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 – Macronutrient composition of control and high fat diets 
expressed as % total weight 
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4.2.2 Protocol 
Surgery was performed as outlined previously in Chapter 2, section 2.2.1.  Following the 
surgical procedure mean arterial blood pressure was allowed to stabilise for 1 hour, after 
which a 2 hour infusion of insulin (10 mU/min/kg) was initiated.  A 30% glucose solution 
(wt./vol.) was infused at a variable rate to maintain basal blood glucose concentrations over 
the course of the experiment.  Arterial blood glucose levels were measured every 10 minutes 
for the first hour, and every 15 minutes in the second hour of the clamp procedure using a 
glucose analyser (YSI 2300).  Measurement of the blood glucose levels allowed the glucose 
infusion rate (GIR) to be adjusted accordingly to maintain basal levels.  Figure 4.1 provides a 
detailed experimental protocol.  Muscle glucose uptake was assessed as outlined in Chapter 
2, section 2.2.2.     
 
 
Figure 4.1 – Experimental protocol of hyperinsulinemic euglycaemic clamp procedure 
in vivo.  Following surgical preparation a 60 minute equilibration period was allowed for 
stabilisation of blood pressure.  Following this a continuous infusion of insulin (10 
mU/min/kg) was commenced and continued for 120 minutes.  A 30% (wt/vol) glucose 
infusion was initiated shortly after the commencement of the insulin infusion in order to 
maintain basal blood glucose levels.  This was assessed by arterial blood sampling ( ).  At 
75 minutes a bolus of 2-DG (20 µCi) was administered and radioactive plasma samples          
( ) were collected at 80, 85, 90, 105, and 120 minutes to determine the clearance of 
plasma 2-DG.  At the conclusion of the experiment arterial plasma samples were collected for 
the determination of hindlimb glucose uptake ( ).  After samples were taken at 120 
minutes animals were sacrificed and calf and epididymal fat pads were immediately excised, 
weighed (epididymal fat pads only) and freeze clamped in liquid nitrogen and stored at -80ºC.   
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4.2.3 Gene expression  
Expression of inflammatory markers was performed by two step reverse transcription real-
time PCR (RT-q-PCR).  RNA was first extracted from skeletal muscle and adipose tissue 
samples and reverse transcribed using SuperScript III (Invitrogen) to obtain cDNA as 
described previously in Chapter 2, section 2.3.  Real time PCR (qPCR) was performed using 
SYBR Green (Qiagen) to amplify the target DNA sequence and quantify gene expression of 
the chosen inflammatory markers (iNOS, TNFα, MCP-1, and EMR1) as described in Chapter 
2, section 2.3.  Inflammatory gene expression is shown as the relative expression to the 
housekeeper S9.  The gene expression measurements were powered to detect changes of 50% 
or greater.   
 
 
4.2.4 Data and statistics 
Data is present as means ± SEM and statistical analysis was performed using SigmaStat 
(Systat Software Inc).  Comparisons between control and high fat fed rats were made using 
un-paired Student’s t-test.  Comparison of time-series measurements in each group was 
performed by two-way repeated measures ANOVA.  When a significant difference of p<0.05 
was detected, pairwise comparisons by Student-Newman-Keuls test was used to assess 
treatment differences.   
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4.3 Results   
 High fat feeding produced significant adiposity with short-term feeding interventions (1 and 4 
weeks), with the epididymal fat pad mass being significantly increased in high fat fed rats 
compared to matched controls (Figure 4.2, B).  With 1 week of high fat feeding this increased 
adiposity was reflected in a significant increase in body weight, however after 4 weeks of 
high fat feeding overall body weight was no different from control animals despite 
significantly increased adipose tissue mass (Figure 4.2, A).  In comparison there is a clear 
lack of adiposity in long-term high fat fed rats (8 and 12 weeks) after dietary intervention 
with the epididymal fat pad mass of high fat fed rats being no different from matched controls 
(Figure 4.2, B).  This lack of adipose tissue accumulation was also reflected by the body 
weight of long-term high fat fed rats also being no different from control animals for both 8 
and 12 week time-points (Figure 4.2, A).     
Whole body insulin sensitivity was not found to be impaired in high fat fed rats at either the 4 
or 12 week time-points with this 58% high fat diet.  Four week high fat fed rats showed no 
change in the rate of glucose infusion during the hyperinsulinemic euglycaemic clamps 
(Table 4.2, Figure 4.3, A) and glucose uptake within skeletal muscle was also found to be no 
different between high fat fed and control animals.  Long-term high fat feeding produced no 
impairment of whole body insulin sensitivity during hyperinsulinemic euglycaemic clamps.  
In fact, these animals showed a significant increase of whole body insulin sensitivity 
measured by the clamp procedure compared to controls (Table 4.2, Figure 4.3, B).  This 
increase in whole body insulin sensitivity was not associated with increased glucose uptake 
by the skeletal muscle (Table 4.2).  Short-term high fat feeding (1 week) was also performed 
in older animals that were age-matched with the 12 week time-course (data not shown).  
Although 1 week of high fat feeding produced significant obesity in young animals the same 
effect did not occur in animals that were older (CON 1.71 ± 0.13 vs HFD 1.71 ± 0.09).  These 
animals also showed intact insulin sensitivity and metabolic responses with GIR (CON 21.0 ± 
0.2 vs HFD 21.6 ± 0.2) and skeletal muscle glucose uptake (CON 21.9 ± 1.5 vs HFD 20.9 ± 
2.0) being no different from matched controls.   
Pro-inflammatory and macrophage markers were not found to be significantly expressed in 
the adipose tissue or skeletal muscle of rats after short (4 week) or long-term (12 week) high 
fat feeding interventions compared to matched controls for any of the inflammatory markers 
analysed (Table 4.3, A-B).   
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Figure 4.2 – Effect of a high fat diet (58% calories) on (A) weight gain and 
(B) adiposity over short and long-term interventions between Control () 
and high fat fed () rats.  Epididymal fat pads were excised and weighed 
immediate after removal and mean wet weight as percentage of body weight is 
shown for each group ± SEM for n = 5-9 rats with * = p < 0.05 and ** = p < 0.01 
indicating significant difference from matched control animals by Student’s t-test. 
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Figure 4.3 – Effect of high fat feeding (58% calories) on whole body insulin sensitivity in control 
() and high fat fed animals () by hyperinsulinemic euglycaemic clamp for (A) 4 week and (B) 12 
week interventions. Data shows means ± SEM for n = 8-9 rats in each group. * = p<0.05 indicates 
statistical difference between control and HFD groups.  Statistical analysis was performed using two-way 
repeated measures ANOVA.     
Table 4.2 - Metabolic responses and insulin sensitivity in short and long-term high 
fat fed rats using a 58% high fat diet. 
 
Metabolic parameters were measured by performing 10 mU hyperinsulinemic euglycaemic 
clamps in anaesthetised animals, with glucose infusion rate reflecting whole body insulin 
sensitivity.  Muscle glucose uptake was calculated by 2-deoxy-D-Glucose uptake during 
final 45 minutes of clamp procedure.  Data shows means ± SEM for n = 8-9 rats in each 
group. Statistical analysis was performed by Student’s t-test and GIR analysis was 
performined by two-way repeated measures ANOVA.   
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Table 4.3 – Comparison of inflammatory gene expression in visceral adipose 
tissue and skeletal muscle of short and long-term high fat fed rats and controls 
 
Inflammatory gene expression was measured by quantitative real time PCR 
(qPCR) and is shown as the relative expression to the housekeeper S9.  An 
inflammatory response was not found to be expressed in (A) visceral adipose 
tissue or (B) skeletal muscle of both short (4 week) and long-term (12 week) high 
fat fed rats compared to matched control animals.  Data shows means ± SEM for    
n = 8–9 rats in each group.  Statistical analysis was performed using Student’s       
t-test.  Unless indicated, differences in individual marker expression between 
control and HFD at 4 and 12 week time-points are not significant.   
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4.4 Discussion 
 
Although diets with very high fat contents have been widely reported to produce significant 
obesity and insulin resistance in rodents, the results in the current study showed that a diet in 
which 58% of the calories were derived from fat was ineffective at inducing an obese and 
insulin resistant phenotype in rats after both short and long-term dietary interventions.  Rats 
fed the high fat diet showed significant adiposity after short-term dietary interventions (1 and 
4 weeks), however longer interventions (8 and 12 weeks) showed that high fat fed rats were 
no more obese than control animals (Figure 4.2, B).  Therefore the adiposity induced with 
short-term feeding was only transient and was not maintained or developed with longer 
intervention of this diet.  Surprisingly insulin sensitivity measured by GIR during 
hyperinsulinemic euglycaemic clamp was found to be unchanged in 4 week high fat fed 
animals compared to controls, despite significantly increased adiposity (Table 4.2, Figure 4.3, 
A) unlike what has been previously reported within the literature by others which show 
significant impairments to insulin-mediated responses after 4 weeks [86, 176].   
Unexpectedly, insulin sensitivity was found to be significantly increased in high fat fed rats 
after 12 weeks (Table 4.2, Figure 4.3, B), however the reasons for this response are unclear.  
Despite this response skeletal muscle glucose uptake in these animals was found to be no 
different from control animals (Table 4.2).  The results obtained in this study were surprising 
as others have shown success with inducing an obese and insulin resistant phenotype in rats 
after similar high fat interventions [86, 176, 198, 211].     
 
Comparison of the adiposity obtained after 4 weeks of high fat feeding was comparable to 
that obtained in similar studies in rats within the literature [86, 176].  However despite a 
similar degree of adiposity, insulin sensitivity and metabolic responses were not impaired in 
these animals but has been reported in other high fat studies.  Studies conducted by St-Pierre 
using the same degree of high fat diet (58% calories derived from fat) and methods for 
measuring insulin sensitivity showed that 4 weeks of high fat dietary intervention is able to 
produce significant adiposity and impaired whole body insulin sensitivity in rats, and 
included impaired microvascular blood flow response in skeletal muscle [86, 176].  In 
particular skeletal muscle glucose uptake was found to be significantly blunted in high fat fed 
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rats (Δ -21% with 10 mU/min/kg insulin clamp) when compared to controls, and whole body 
insulin sensitivity was found to be significantly impaired in rats that had undergone 4 weeks 
of high fat feeding.  GIR was found to be reduced after only 10 minutes of the 2 hour insulin 
clamp and this reduction was maintained for the duration of the clamp protocol [86].  It was 
expected that our rats would achieve a comparable degree of adiposity and a similar level of 
impaired insulin sensitivity after 4 weeks, and become progressively worse by 12 weeks.  
Therefore the lack of these impaired metabolic responses in our study was highly surprising.  
One of the main discrepancies between our study and those done by St-Pierre is the strain of 
rat breed used, with those by St-Pierre performed in Hooded Wistar rats [86, 176], whilst the 
current study was conducted in Sprague Dawleys.  However, Sprague Dawley rats have also 
been reported to develop obesity and insulin resistance after high fat feeding with diets 
containing a lower fat content for 4 week interventions [138, 180].  It is therefore unclear as 
to why our rats did not produce similar metabolic impairment after intervention with a 58% 
high fat diet, but may be due to reduced palatability of the diet.   
 
The inflammatory markers chosen for this study, TNFα, iNOS, and MCP-1, have been 
highlighted within the literature for their association with obese and insulin resistant states 
[122, 126, 127, 129].  These inflammatory markers have been shown to have the potential for 
impairing insulin sensitivity and altering vascular responses which may result in insulin 
mediated microvascular dysfunction [126-129, 143, 154, 187].  Significant inflammatory 
responses within the literature have been reported as large fold changes such as 2-3 fold 
increases or more of gene expression within tissues [26, 71, 124].  Although the lack of 
significant up-regulation of inflammatory gene expression in the tissues of high fat fed rats at 
either time-point was initially surprising (Table 4.3), the lack of well-developed obesity in 
these animals could explain why this response was not seen (Figure 4.2, B).  Studies 
conducted in mice have shown that inflammation plays a role in more established and chronic 
insulin resistant and obese states while the initial onset of obesity is independent of an 
inflammatory response [26].  However, without an obese state, inflammation is unlikely to be 
observed.  Inflammation is routinely reported in well-developed and chronic obese states [19, 
26, 27, 188].  Therefore a model of diet-induced obesity with more overt adiposity than what 
was obtained would potentially provide better conditions for inflammation to be induced.  It 
is possible that the higher fat content of this high fat diet is potentially not as appealing or as 
palatable as those containing less fat, and as a results may not be consumed in excess to 
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produce significant obesity, however measurement of food and calorie intake could confirm 
this [214].   
 
This study has shown that a simple high fat feeding regimen in rats is not an effective method 
for producing a model of obesity-associated insulin resistance similar to that seen in humans.  
The reasons for this apparent variability in the outcomes of high fat feeding has not been 
widely identified or addressed within the literature.  However some studies have identified 
that there are distinct variations in the phenotype induced through high fat feeding 
interventions [204, 215].  These varied outcomes from high fat feeding could potentially be 
due to high fat diets being classified as simply a ‘high fat content’ and not strictly 
standardised between studies [204].  Studies have shown that different dietary fats produce 
different responses in regards to weight gain and metabolic responses.  Animal fats and plant 
oils high in omega 6 and omega 9 fatty acids have been shown to be effective at generating 
significant obesity and insulin resistance in rodents whereas animals fed fish oil and omega 3 
fatty acids in high fat dietary studies did not develop these same responses [204, 215-217].  
The type of dietary fat used in high fat feeding interventions is highly variable within the 
literature and some studies use diets with a combination of different fat sources [86, 179, 215, 
218].  This variation of fatty acid compositions can therefore potentially produce varying 
results across studies especially in regards to weight gain and insulin sensitivity; therefore the 
type of high fat diet used in obesogenic dietary studies should be examined in detail to 
determine its suitability as a model of diet-induced metabolic dysfunction [204].  Comparison 
of the fat content of the control and high fat diets used in this study show that the high fat diet 
contains 36% fat wt/wt compared to the 4.8% fat wt/wt of the control diet.  This equates to 
the digestible energy derived from fat being 58% for high fat and 11% for control diets 
(Table 4.1, Section 4.2).  Breakdown of the dietary fat components into monounsaturated, 
polyunsaturated, and saturated fat species shows that the high fat diet contains a significant 
amount of saturated fat with more than half of the total fat content derived from saturated fat 
alone.  Although diets high in fat have been shown to produce obesity and insulin resistance 
in humans and animals, high intake of saturated fats in particular have been associated with 
producing a more significant phenotype than high intake of other fat species [218, 219].  
Therefore it remains surprising that long-term high fat feeding did not produce a significant 
response in our rats.  However the composition of fat within the high fat diet may not be the 
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cause for the lack of adiposity and impaired insulin sensitivity in our animals and may be a 
result of other factors.   
   
Another potential reason for the unsuccessful response to this diet could be its taste.  The 
high fat content of the diet may not be palatable enough to stimulate excessive over-eating to 
result in significant adiposity, especially over longer dietary interventions [214, 220, 221].  
Within this study, increased adiposity with high fat feeding was seen in younger animals on 
the diet for only short durations, while the long-term dietary intervention did not produce the 
same effect (Figure 4.2, B).  As food and calorie intake was not measured in this experiment, 
the true palatability and consumption of the 58% high fat diet can only be hypothesised.  It is 
possible that the high fat diet was initially well received and may be seen as a novel food 
choice compared to standard laboratory chow, however as the intervention continues this 
same diet may become monotonous and less palatable.  A true obesogenic diet is therefore 
not always straightforward and a straight exchange of carbohydrate to fat may therefore not 
be an effective method for investigating diet-induced obesity and its associated health 
complications in all animal models.  Studies have shown that rats exhibit food selection and 
have specific meal preferences with taste perception and flavour response strongly 
influencing diet consumption and over-eating [221-224].  Sensory factors have been 
identified as being equal to or more important than dietary composition in regards to food 
intake and excessive food consumption [225].  A high degree of adipose tissue accumulation 
is believed to be due to a combination of both excessive food consumption and poor dietary 
intake which includes highly processed foods, a high intake of bad fats, salt, and sugar [188, 
212].  Therefore obesogenic diets should not always be associated with a straightforward 
calorie swap of one dietary component for another.  Varied taste and dietary components 
such as fat and sugar have been shown to be more effective for inducing hyperphagia than 
each component on their own [226].   
 
High fat feeding is routinely used to study diet-induced obesity in laboratory animals.  This 
method of dietary interventions has been well reported within the literature and has been 
shown to produce significant obesity with impaired metabolic responses [117, 138, 176, 178].  
However surprisingly, this study has shown that the effectiveness of high fat feeding is 
somewhat variable.  Despite its reported success within the literature [26, 86, 117, 176], the 
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results from the current study found the use of a very high fat diet (58% calories derived from 
fat) to be less effective at inducing a model of obesity-associated insulin resistance than the 
lower fat content diet employed in Chapter 3, as our rats showed no impairment to insulin 
sensitivity, increased inflammatory expression, or significant and chronic obesity with both 
short and long-term interventions.  The lack of significant or chronic obesity with this diet is 
the major limitation of this study and did not allow a study of the interaction between obesity, 
inflammation and insulin resistance.  However the results highlight that high fat feeding is 
not always an effective way of producing an obese state with impaired metabolic responses.  
High fat diet treatments may only be more effective at one stage or timeframe and may only 
provide a short-term snapshot as opposed to long-term health complications of the obese 
state; as shown by the transient adiposity seen in rats fed this higher fat diet (Figure 4.2, B).  
Therefore care is needed when undertaking these types of investigations and factors such as 
dietary fat species, diet palatability, and variation should be taken into consideration [188, 
215, 223].  Studies have shown that highly varied and palatable diets based on human snack 
food items, often referred to as the ‘cafeteria-style diet’, have been highly effective at 
inducing significant hyperphagia and obesity in rats [188, 220, 227, 228].  Further 
investigation into its ability to produce and maintain chronic obesity over long interventions 
would prove valuable in establishing its suitability as an alternative model to study the 
relationship between diet-induced obesity and inflammation, and the influence inflammation 
may have on metabolic dysfunction especially impaired vascular responses.   
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CHAPTER 5 
 
 
 
CAFETERIA-STYLE DIET INDUCES 
SIGNIFICANT OBESITY AND 
INSULIN RESISTANCE, BUT NOT 
INFLAMMATION IN RATS 
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5.1 Introduction 
 
Diets commonly used for obesogenic dietary studies often involve a simple exchange of 
calories derived from carbohydrate for those derived from fat [86, 205, 211].  Despite studies 
within the literature showing success with this method for inducing obesity, insulin 
resistance, and inflammation [26, 86, 138], experiments shown in Chapters 2 and 3 
investigating high fat feeding over a range of time points have indicated that this is not 
always the case.  It is important to note that this type of diet modification of simply swapping 
carbohydrate to fat is not a true representation nor does it provide the robustness of the poor 
diet habits adopted by humans that lead to obesity and its associated health complications 
[188, 229].  It has been shown that experimental diets consisting of a variety of energy dense 
and palatable snack foods, such as the cafeteria-style diet, are highly effective at producing a 
vast degree of obesity with significant metabolic impairment [188].  This type of diet is also a 
more accurate representation of poor food choices present in Western society where obesity 
has reached epidemic proportions.   
 
The cafeteria-style diet consists of a variety of highly palatable and calorie dense food items 
often containing significant amounts of fat, sugar, and salt.  Although the composition of this 
diet varies considerably between studies, food items with a high energy density are selected 
and these include snack food items such as peanut butter, cookies, cheese, condensed milk, 
cereals, and bacon [188, 220, 227, 230, 231].  The high palatability of these items in addition 
to a variety of different options on offer is believed to be what makes this diet effective at 
inducing hyperphagia and significant weight gain.  Previous studies using this style of diet 
[188, 220, 227, 228, 232], have shown that rats given free access to these palatable foods 
produce excessive weight gain and dietary obesity with impaired metabolic responses.  
However despite its reported effectiveness in inducing obesity, the use of this cafeteria-style 
diet is highly variable within the literature, with both its availability (food items only given 
for specific time periods versus constant availability) and the number of food items (a few 
items interchanged daily versus all options available) on offer [220, 222, 227, 228].   
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The use of cafeteria diets proved a popular dietary intervention for investigating obesity in 
the 1980s [222, 232-235], however its use appeared to fall out of favour potentially due to 
commercial obeseogenic diets in pellet form becoming widely available for laboratory 
research which allows for the diet to consist of more purified and controlled components.  
Interestingly the use of cafeteria-style diets has seen somewhat of a resurgence in recent years 
[188, 220, 227, 228, 230, 236-238], however the exact reason for this has not been openly 
discussed in detail.  It has been highlighted that foods high in sugar and fat are rewarding and 
are linked to binging episodes and addiction-like responses in animals [229, 237].  A large 
portion of recent studies using cafeteria-style diets have used them as a tool to investigate 
feeding patterns and behaviour in animals.  Many of these studies focus on neurological 
responses such as appetite regulation, reinforcement, addiction-like behaviour, and have been 
associated with chronic over-consumption of palatable foods especially with extended 
interventions [220, 237-243].  The success of this cafeteria-style diet to induce significant 
hyperphagia and obesity allows for the mechanisms of feeding behaviour in relation to 
excessive nutrient intake and poor dietary health to be investigated within these studies.   
However despite a large amount of research being conducted in this area, cafeteria-style diets 
are still rarely used to study obesity-associated health complications such as inflammation 
and the metabolic syndrome [188, 230].    
 
Sampey et al [188] has highlighted the fact that although a number of animal models 
examining dietary obesity exist, there is a lack of studies comparing these different diet 
treatments in rodents.  Direct comparisons between different dietary interventions, such as 
commonly used high fat diets and cafeteria-style diet, have not been adequately examined or 
evaluated, and it has been alluded to that monotonous and rather bland laboratory diets – 
including high fat diets despite enhanced flavouring to improve palatability – may not reflect 
the normal regulation of feeding behaviour or degree of weight gain and metabolic responses 
that is possible in these animals compared to more varied and palatable diets.  Therefore more 
comprehensive studies comparing different methods of diet-induced obesity are required in 
order to determine the effectiveness and suitability of dietary interventions for research 
purposes.  For that reason this study aimed to compare the effectiveness of a cafeteria-style 
diet at inducing significant obesity to that obtained from high fat feeding, and whether the 
increased adiposity is able to be maintained over long periods of dietary intervention.  If these 
61 
 
criteria were met, a second, more important aim (for this thesis) was to determine whether the 
increased adiposity was associated with inflammation in adipose tissue.     
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5.2 Materials and Methods   
 
5.2.1 Animals 
Male Sprague Dawley rats approximately 4 weeks of age were obtained from the University 
of Tasmania Central Animal Facility.  On arrival rats were split into equal groups.  One group 
was provided with a commercially available control diet (6% fat wt/wt) (Barrastoc), while the 
other was provided with control diet (6% fat wt/wt) and a ‘cafeteria-style’ diet consisting of 
two different human snack food items which were interchanged daily (Table 5.2).  Of the 
snack foods chosen for the cafeteria-style diet, one high protein and one sweet or savoury 
item was selected for each day.  Food items selected for this diet were based on studies that 
have used this cafeteria-style dietary intervention previously [188, 227, 230, 232].  All food 
items, along with drinking water, were available ad libitum for 4 and 12 weeks.  All food 
items were purchased from Woolworths supermarket, Hobart, Tasmania, and were weighed 
daily to monitor food consumption.  
Macronutrients in these diets are shown in Table 5.1.   
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 – Diet breakdown (% Calories) of control and cafeteria-style diets 
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5.2.2 Protocol 
Surgery was performed as outlined previously in Chapter 2, section 2.2.1.  Following the 
surgical procedure mean arterial blood pressure was allowed to stabilise for 1 hour, after 
which a 2 hour infusion of insulin (10 mU/min/kg) was initiated.  A 30% glucose solution 
(wt./vol.) was infused at a variable rate to maintain basal blood glucose concentrations over 
the course of the experiment.  Arterial blood glucose levels were measured every 10 minutes 
for the first hour, and every 15 minutes in the second hour of the clamp procedure using a 
glucose analyser (YSI 2300).  Measurement of the blood glucose levels allowed the glucose 
infusion rate (GIR) to be adjusted accordingly to maintain basal levels.  Figure 5.1 provides a 
detailed experimental protocol.  Muscle glucose uptake was assessed as outlined in Chapter 
2, section 2.2.2.     
Table 5.2 – Food items used in cafeteria-style diet with macronutrient profile 
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5.2.3 Gene expression  
Expression of inflammatory markers was performed by two step reverse transcription real-
time PCR (RT-q-PCR).  RNA was first extracted from skeletal muscle and adipose tissue 
samples and reverse transcribed using SuperScript III (Invitrogen) to obtain cDNA as 
described previously in Chapter 2, section 2.3.  Real time PCR (qPCR) was performed using 
SYBR Green (Qiagen) to amplify the target DNA sequence and quantify gene expression of 
the chosen inflammatory markers (iNOS, TNFα, MCP-1, and EMR1) as described in Chapter 
2, section 2.3.  Inflammatory gene expression is shown as the relative expression to the 
Figure 5.1 – Experimental protocol of hyperinsulinemic euglycaemic clamp procedure 
in vivo.  Following surgical preparation a 60 minute equilibration period was allowed for 
stabilisation of blood pressure.  Following this a continuous infusion of insulin (10 
mU/min/kg) was commenced and continued for 120 minutes.  A 30% (wt/vol) glucose 
infusion was initiated shortly after the commencement of the insulin infusion in order to 
maintain basal blood glucose levels.  This was assessed by arterial blood sampling ( ).  At 
75 minutes a bolus of 2-DG (20 µCi) was administered and radioactive plasma samples          
( ) were collected at 80, 85, 90, 105, and 120 minutes to determine the clearance of 
plasma 2-DG.  At the conclusion of the experiment arterial plasma samples were collected for 
the determination of hindlimb glucose uptake ( ).  After samples were taken at 120 
minutes animals were sacrificed and calf and epididymal fat pads were immediately excised, 
weighed (epididymal fat pads only) and freeze clamped in liquid nitrogen and stored at -80ºC.   
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housekeeper S9.  The gene expression measurements were powered to detect changes of 50% 
or greater.   
 
 
5.2.4 Data and statistics 
Data is present as means ± SEM and statistical analysis was performed using SigmaStat 
(Systat Software Inc).  Comparisons between control and high fat fed rats were made using 
un-paired Student’s t-test.  Comparison of time-series measurements in each group was 
performed by two-way repeated measures ANOVA.  When a significant difference of p<0.05 
was detected, pairwise comparisons by Student-Newman-Keuls test was used to assess 
treatment differences.   
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5.3 Results   
   
Both short and long term interventions with the cafeteria-style diet produced overt obesity 
with epididymal fat pad mass being significantly heavier in cafeteria diet-fed animals 
compared to controls (Figure 5.1, B).  This excessive fat accumulation also resulted in 
significantly elevated body weights of the cafeteria rats compared to control animals at both 
time points (Figure 5.1, A).     
Whole body insulin sensitivity was found to be significantly impaired in the cafeteria diet-fed 
rats for both short and long-term interventions compared to matched controls, as reflected by 
significantly impaired GIR response during insulin clamps and blunted glucose uptake by the 
skeletal muscle within these animals (Figure 5.2).   
Despite the presence of significant obesity and insulin resistance in rats fed this cafeteria-
style diet, expression of pro-inflammatory and macrophage markers were surprisingly found 
to not be up-regulated in the adipose tissue after both short and long-term dietary 
interventions (Tables 5.1, A).  Although a significant increase in the expression of iNOS was 
noted in the adipose tissue of long-term cafeteria diet-fed rats (Table 5.1, A), the lack of other 
pro-inflammatory or macrophage markers being up-regulated at the same time indicates that 
an inflammatory response was not occurring and that the increased expression of iNOS at this 
time point is potentially due to other un-related mechanisms.  Furthermore, although the 
increase in iNOS expression at 12 weeks was significant, the change is quite small and 
confirms that this response is unlikely to reflect an inflammatory state.  Due to inflammation 
not seen within the adipose tissue (Table 5.1, A), the lack of inflammation within skeletal 
muscle was not surprising (Table 5.1, B).   
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Figure 5.2 – Effect of a cafeteria-style diet on (A) body weight and (B) 
adiposity over short and long-term interventions between Control () and 
cafeteria () diet-fed rats.  Epididymal fat pads were excised and weighed 
immediate after removal and mean wet weight as percentage of body weight is 
shown for each group ± SEM for n = 6-8 rats with   * = p < 0.05, ** = p < 0.01,  
*** = p < 0.001 indicating significant difference from control animals by Students 
t-test. 
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Table 5.3 - Metabolic responses and insulin sensitivity in short and long-term 
cafeteria diet-fed rats. 
 
Metabolic parameters were measured by performing 10 mU hyperinsulinemic euglycaemic 
clamps in anaesthetised animals, with glucose infusion rate reflecting whole body insulin 
sensitivity.  Muscle glucose uptake was calculated by 2-deoxy-D-Glucose uptake during 
final 45 minutes of clamp procedure.  Data shows means ± SEM for n = 6-8 rats in each 
group. Statistical analysis was performed by Student’s t-test and GIR analysis was 
performined by two-way repeated measures ANOVA.   
Figure 5.3 – Effect of cafeteria-style diet on whole body insulin sensitivity in control () and CAF 
animals () by hyperinsulinemic euglycaemic clamp for (A) 4 week and (B) 12 week interventions.  
Data shows means ± SEM for n = 6-8 rats in each group. *** = p<0.001 indicates statistical difference 
between control and CAF groups.  Statistical analysis was performed using two-way repeated measures 
ANOVA.     
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Tables 5.4 – Comparison of inflammatory gene expression in adipose and 
skeletal muscle of cafeteria diet-fed rats and controls after short and long-
term dietary intervention   
 
A pro-inflammatory response was not found to be expressed in (A) visceral adipose 
tissue or (B) skeletal muscle of rats fed a cafeteria-style diet compared to control 
animals for both 4 and 12 week dietary interventions.  Data shows means ± SEM for n 
= 6-8 rats in each group. * indicates significant difference (p<0.05) from control 
animals by Students t-test.  A significant increase was noted in the expression of iNOS 
in the adipose tissue of long-term cafeteria diet-fed rats (12 weeks) (A), however the 
lack of up-regulated expression of other inflammatory markers indicates the lack of a 
true inflammatory response occurring. 
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5.3 Discussion 
 
The cafeteria-style diet was shown to be a highly effective tool for producing significant 
visceral adiposity with significant impairment of metabolic responses in rats that was 
sustained for 12 weeks.  After 4 weeks of intervention epididymal fat pads were 
approximately double the weight of fat pads from control animals, however long-term 
cafeteria-diet intervention resulted in especially excessive obesity with epididymal fat pads 
being more than three times the weight of age-matched control diet-fed animals (Figure 5.2, 
B).  Therefore not only was obesity maintained over the longer intervention but it became 
more developed as dietary intervention progressed.  This obesity was also associated with the 
body weight of these animals being significantly increased compared to controls for both 
time-points (Figure 5.2, A).  Cafeteria diet-fed rats also showed significant impairment of 
whole body insulin sensitivity and glucose uptake by the skeletal muscle followed both short 
and long-term dietary interventions (Table 5.3, Figure 5.3, A-B).  Long-term cafeteria diet 
further reduced the GIR of cafeteria diet-fed rats compared to controls (Table 5.3, Figure 5.3, 
B).   
 
Compared to previous results obtained with high fat diets (Chapters 3 and 4), the cafeteria-
style diet has shown to be an effective tool for producing diet-induced obesity and insulin 
resistance in rats.  The degree of adiposity in 4 week cafeteria diet-fed rats is almost double 
what was obtained with a 58% fat diet at 4 weeks, and is actually elevated about what was 
obtained after 12 weeks of high fat feeding.  Looking at the adiposity of 12 week cafeteria 
diet rats shows that fat pad weight of these animals is more than double that of 12 week 58% 
fat rats (Chapter 4, Figure 4.2, B).  This significant adiposity of cafeteria diet-fed rats was 
also associated with significant impairment to insulin sensitivity at both time-points, which 
was not seen in 58% high fat fed rats (Chapter 4, Table 4.2).  Therefore these results 
emphasise that a more varied and palatable dietary intervention is significantly more effective 
than a diets based solely on increased fat content for producing an obese and insulin resistant 
phenotype in rats.   
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A number of rat studies have used significantly increased body weight as a measurement of 
obesity without directly reporting adipose tissue data [188, 220, 222, 227].  Although the 
significant increase in body weight of animals under dietary intervention can be presumed to 
be due to increased fat accumulation, it has not been quantified.  As shown in this study, 
although the body weights of cafeteria diet-fed rats were significantly heavier than controls at 
both 4 and 12 week time-points, their adiposity was even more significant (Figure 4.2, B).  In 
studies that report adipose tissue measurements, the degree of adiposity after 4 to 8 weeks of 
a cafeteria-style diet is comparable to that achieved in the current 4 week time-course with 
rats showing approximately a doubling of adipose tissue weight compared to control animals 
[244-246].  Long-term studies in mice (approximately 12 to 15 weeks) have shown an 
increase of adiposity 3 to 4 times that of control animals [247, 248].  This is comparable to 
the adiposity observed in the 12 week cafeteria diet-fed rats (Figure 4.2, B).  That is, the 
cafeteria diet, but not the high fat diet, can achieve a similar degree of adiposity as obese 
mice in which inflammation is evident.     
 
Although the cafeteria-style diet produces a robust model of diet-induced obesity, it can 
create difficulties within a research setting.  While the cafeteria diet is loosely defined as the 
feeding of Western-style snack food items, the fact is that this diet is not standardised and 
highly varied diet compositions have been reported within the literature [188, 207, 220, 227, 
228, 230, 232, 237].  This can complicate comparisons between different cafeteria diet 
studies in contrast to more reproducible commercially available laboratory diets.  Although 
the cafeteria diet is successful at inducing significant obesity in both rats and mice the degree 
of adiposity reported is somewhat variable.  Some studies have reported a doubling of 
adipose tissue mass whilst others report it to be 3 or 4 times higher than controls [244-249].  
Reasons for these differences could include the variable nature of the cafeteria-style diets 
reported in the literature [188, 207, 220, 227, 230, 232, 249].  Accurate recording of food 
intake during dietary interventions can be challenging, however the cafeteria-style diet can 
introduce added complexity or error due to the range of different food items on offer.  The 
nature of certain food items often selected include biscuits, cakes and potato chips to which 
are prone to crumble, spillage of liquids such as condensed milk, and the desiccation of 
certain foods such as meats and cheese provides sources of error that do not occur with low 
water content laboratory chows [227].  Despite this, the effectiveness of the cafeteria-style 
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diet has shown that both the diet palatability and variability are important factors to consider 
in regards to developing significant diet-induced obesity [214, 220, 223].   
 
Both results from the dietary studies in this thesis and research done by others have shown 
that palatability and variety contribute towards inducing hyperphagia and overt obesity [188, 
220, 223, 227].  It is important to note that some commercial diets alter their palatability and 
include the addition of flavouring to enhance taste response and reception in research animals 
[224, 225].  Therefore comparison of high fat fed animals to those fed a cafeteria-style diet 
shows that diet variability in particular may determine food intake and hyperphagia in these 
animals.  A number of studies have investigated the feeding behaviour of rats and have found 
that rats consume more when multiple food items of different tastes are offered compared to 
when only a single food choice is given [221-224, 250].  Over-eating in rats on this varied 
diet appears to occur due to multiple food items being sampled which as a result increases the 
size of the meals consumed during each feeding period [222].  Therefore it has been 
hypothesised that satiety in rats is sensory-specific and that animals on a cafeteria or varied 
diet have excessive food consumption due to a delayed satiety response [225].   
 
The most surprising finding to come from this study was that even with overt obesity and 
significantly impaired insulin sensitivity, cafeteria diet-fed rats lacked a pro-inflammatory 
response within insulin sensitive tissues, with the lack of inflammation within the visceral 
adipose tissue being especially unexpected (Table 5.4, A-B).  Because of the increased 
adiposity resulting from this diet, an up-regulation of inflammatory and macrophage markers 
was anticipated as inflammation has been widely reported to be present in obese conditions 
and insulin resistance within the literature [18, 19, 26, 27, 199].  However findings from this 
study have shown that inflammation is not significantly expressed in rats despite significant 
obesity and insulin resistance.  Therefore it can be stated that obesity and insulin resistance 
can occur independent of inflammation, and that inflammation is not a prerequisite driving 
factor in the development of impaired metabolic responses in obese states.  Interestingly the 
majority of studies examining obesity-related inflammation have been conducted in mouse 
models [26, 27, 72, 117, 123, 124, 129, 170, 177, 189, 191, 200, 208, 251-253] and greatly 
outnumber similar studies in rats [185, 188, 210, 211, 231].  The exact reason for this has not 
been discussed within the literature, however the results from this study leads us to 
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hypothesise that rats possess mechanisms protecting them against developing significant 
inflammatory responses under these conditions of dietary intervention.   
 
A potential explanation for the lack of an inflammatory response is the ability of adipose 
tissue to exhibit different growth responses during increases in lipid storage.   Healthy 
adipose tissue expansion with adequate blood flow and oxygen availability despite excessive 
lipid accumulation is not associated with an inflammatory response, however inflammation 
has been strongly associated with adipose tissue dysfunction during unhealthy tissue 
expansion.  As stated previously, the exact signalling pathways and mechanisms required for 
both healthy and unhealthy adipose tissue expansion are not well understood, and other 
additional mechanisms including genetic factors, genetic predisposition, and even the gut 
microbiome could be mediators or contributors to this regulation.  Therefore further research 
into these mechanisms will allow for a better understanding as to the full potential of adipose 
tissue in a number of health complications and disease.   
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CHAPTER 6 
 
 
 
METFORMIN RESTORES 
SKELETAL MUSCLE INSULIN 
SENSITIVITY AND 
MICROVASCULAR RECRUITMENT 
IN INSULIN RESISTANT RATS 
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6.1 Introduction 
 
Obesity and insulin resistance are significant causes of health problems worldwide due to 
their link to cardiovascular disease and Type 2 Diabetes [116, 254].  Effective treatment that 
improves or restores insulin sensitivity aims to significantly reduce the morbidity and 
mortality that can occur without intervention.  Lifestyle modifications such as diet, exercise, 
and weight loss remain the most beneficial treatment options for obese and insulin resistant 
individuals.  However drug therapy is also required for patients that are unable to effectively 
implement lifestyle modifications such as exercise and weight loss.  In addition to its ease of 
use drug therapy has more rapid results for controlling symptoms such as hyperglycaemia 
[12, 137, 255-257].  Preferably medication is used in conjunction with lifestyle modifications 
to obtain the most beneficial outcome for patient health.     
 
Because insulin resistance is a key risk factor for the development of Type 2 Diabetes, a 
number of therapeutic agents have the primary action of improving insulin sensitivity [258-
260].  There are two main classes of insulin sensitising drugs used for the treatment of insulin 
resistance.  These include the biguanide and thiazolidinediones groups, with metformin and 
rosiglitazone being the primary drugs in each group respectively [258].  However despite 
their use, the mechanisms of these agents are not understood in detail [254, 258].  
Thiazolidinedione treatment, such as the use of rosiglitazone, has been shown to improve 
insulin sensitivity by stimulating the uptake of glucose by skeletal muscle [261-263].  
Although this family of drugs have proven to be effective at improving hyperglycaemia, their 
use has become controversial due to their association with increased risk of cardiovascular 
complications such as heart failure and stroke [264, 265].   
 
In comparison, metformin has shown significant success with improving insulin sensitivity 
within insulin resistant individuals, and is currently the preferred drug treatment available for 
the regulation and control of blood glucose levels, having few adverse side effects [260, 265].  
From the biguanide family, metformin is now the preferred drug for the treatment of type 2 
diabetes [255, 266].  It is highly effective at reducing blood glucose levels, primarily through 
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the suppression of hepatic glucose production by the liver [267, 268], and it has also been 
shown to increase skeletal muscle glucose uptake [269, 270] however this action is still 
somewhat contentious [259, 266].  In addition to its insulin sensitising actions, metformin 
also significantly lowers the risk of cardiovascular-related death, such as by heart attack and 
heart failure [255, 271].  Cardiovascular disease is one of the leading causes of mortality in 
insulin resistance and type 2 diabetes [272].  Therefore metformin’s ability to effectively 
reduce these events, in addition to its ability to improve insulin sensitivity, is one of the 
primary reasons it has become the preferred treatment option.   
 
A number of studies have investigated the effect of metformin treatment on the incidence of 
cardiovascular events, such as myocardial infarction, heart failure, and stroke, in human 
subjects, which associate with macrovascular dysfunction [273, 274].  Many studies which 
have investigated metformin’s ability to alter vascular responses have done so in regards to 
endothelium-dependent and endothelium-independent vasodilation, often by the use of 
acetylcholine and sodium nitroprusside respectively [272, 275, 276].  Although these studies 
have provided insight into some of the mechanisms surrounding vascular dysfunction, few 
studies have been conducted to investigate metformin’s ability to alter microvascular 
responses such as capillary recruitment within insulin resistant skeletal muscle in vivo.  Under 
normal conditions insulin recruits additional blood flow within the microvasculature of 
muscle to allow for increased substrate and glucose delivery to the skeletal myocytes [23].  
However impaired capillary recruitment and blood flow within the microvascular has been 
identified as a defect leading to the early development of insulin resistance in muscle [86].  
As metformin has been shown to have some vascular action in addition to significantly 
improving hyperglycaemia and insulin sensitivity in insulin resistant individuals, it is possible 
that it also acts upon the microvasculature to improve the delivery of glucose to muscle via 
the recruitment of capillary blood flow.   
 
What is unclear about metformin’s actions in insulin resistance is whether it improves muscle 
insulin sensitivity as a result (at least in part) of improved microvascular perfusion, and 
whether this occurs by opposing the effects of inflammation, as opposed to affecting other 
factors that impair insulin signalling such as altered lipid metabolism and distribution.  
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Metformin has been reported to have anti-inflammatory effects and these occur irrespective 
of diabetes status [277].  Although initially hypothesised in this thesis that diet-induced 
obesity would be accompanied by inflammation, its repeated absence offers an opportunity to 
establish whether metformin’s insulin sensitising actions in muscle (i) involve improved 
muscle microvascular blood flow and (ii) results from an anti-inflammatory action or not.  An 
absence of improved insulin sensitivity with metformin treatment would then suggest that its 
anti-inflammatory action is critical.  Thus the aim of this chapter was to investigate whether 
the loss of whole body muscle and microvascular insulin sensitivity due to diet-induced 
obesity could be restored by metformin treatment.   
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6.2 Materials and Methods 
 
6.2.1 Animals 
Male Sprague Dawley rats approximately 4 weeks of age were obtained from the University 
of Tasmania Central Animal Facility.  On arrival rats were split into equal groups with all rats 
receiving a high fat diet (41% calories derived from fat) ad libtitum for 4 weeks.   
One of the high fat diet groups was also treated with metformin for the final 2 weeks of 
dietary intervention.  Metformin was given at a dose of 150mg/kg/day in the drinking water 
which was monitored daily and changed every 2 to 3 days.  All drinking water, with or 
without metformin, was provided ad libitum. 
Macronutrient content of the 41% high fat diet in comparison to a control diet is shown in 
Table 6.1.     
 
 
 
 
 
 
 
 
 
 
 
Table 6.1 – Macronutrient composition of control and high fat diet 
diets expressed as % total weight 
79 
 
6.2.2 Protocol 
Surgery was performed as outlined previously in Chapter 2, section 2.2.1.  Following the 
surgical procedure mean arterial blood pressure was allowed to stabilise for 1 hour, after 
which a 2 hour infusion of insulin (10 mU/min/kg) was initiated.  A 30% glucose solution 
(wt./vol.) was infused at a variable rate to maintain basal blood glucose concentrations over 
the course of the experiment.  Arterial blood glucose levels were measured every 10 minutes 
for the first hour, and every 15 minutes in the second hour of the clamp procedure using a 
glucose analyser (YSI 2300).  Measurement of the blood glucose levels allowed the glucose 
infusion rate (GIR) to be adjusted accordingly to maintain basal levels.  Figure 6.1 provides a 
detailed experimental protocol.  Muscle glucose uptake and skeletal muscle microvascular 
perfusion were assessed as outlined in Chapter 2, section 2.2.2.     
 
 
 
 
 
Figure 6.1 – Experimental protocol of hyperinsulinemic euglycaemic clamp procedure 
in vivo.  Following surgical preparation a 60 minute equilibration period was allowed for 
stabilisation of blood pressure.  Following this a continuous infusion of insulin (10 
mU/min/kg) was commenced and continued for 120 minutes.  A 30% (wt/vol) glucose 
infusion was initiated shortly after the commencement of the insulin infusion in order to 
maintain basal blood glucose levels.  This was assessed by arterial blood sampling ( ).  At 
55 minutes a bolus of allopurinol (10µmol/kg) was given before an infusion of 1-
methylxanthine (1-MX) was started at 60 minutes.  At 75 minutes a bolus of 2-DG (20 µCi) 
was administered and radioactive plasma samples ( ) were collected at 80, 85, 90, 105, 
and 120 minutes to determine the clearance of plasma 2-DG.  At the conclusion of the 
experiment arterial plasma samples were collected for the determination of hindlimb glucose 
uptake ( ).  After samples were taken at 120 minutes animals were sacrificed and calf and 
epididymal fat pads were immediately excised, weighed (epididymal fat pads only) and 
freeze clamped in liquid nitrogen and stored at -80ºC.   
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6.2.3 Gene expression  
Expression of inflammatory markers was performed by two step reverse transcription real-
time PCR (RT-q-PCR).  RNA was first extracted from skeletal muscle and adipose tissue 
samples and reverse transcribed using SuperScript III (Invitrogen) to obtain cDNA as 
described previously in Chapter 2, section 2.3.  Real time PCR (qPCR) was performed using 
SYBR Green (Qiagen) to amplify the target DNA sequence and quantify gene expression of 
the chosen inflammatory markers (iNOS, TNFα, MCP-1, and EMR1) as described in Chapter 
2, section 2.3.  Inflammatory gene expression is shown as the relative expression to the 
housekeeper S9.  The gene expression measurements were powered to detect changes of 50% 
or greater.   
 
 
6.2.4 Data and statistics 
Data is present as means ± SEM and statistical analysis was performed using SigmaStat 
(Systat Software Inc).  Comparisons between groups were made using un-paired Student’s t-
test and two-way ANOVA.  Comparison of time-series measurements in each group was 
performed by two-way repeated measures ANOVA.  When a significant difference of p<0.05 
was detected, pairwise comparisons by Student-Newman-Keuls test was used to assess 
treatment differences.   
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6.3 Results   
 
High fat fed rats that received metformin treatment were significantly lighter in body weight 
compared to high fat fed rats alone (6.2, A), however this was not reflected in a significant 
difference in epididyal fat pad weight (Figure 6.2, A).   
Metformin treatment in high fat fed rats resulted in significantly improved whole body 
insulin sensitivity with both glucose infusion rate during hyperinsulinemic euglycaemic 
clamps significantly improved compared to high fat fed rats without treatment (Figure 6.3).  
In control animals there was no change in whole body insulin sensitivity between animals 
that did and did not receive metformin as shown by GIR (Figure 6.4, A).  In high fat fed 
animals metformin significantly improved whole body insulin sensitivity (GIR) compared to 
high fat fed animals that did not receive metformin.  The improvement in GIR of metformin-
treated high fat fed rats was also shown to be significant compared to control animals (Figure 
6.4, A).  Metformin treatment did not alter glucose uptake by the skeletal muscle of control 
animals (Figure 6.4, B).  Metformin did significantly improve skeletal muscle glucose uptake 
in high fat fed rats compared to high fat fed animals that did not receive metformin, and 
restored it to that of control animals (6.4, B).  Skeletal muscle microvascular perfusion 
remained unchanged in control diet-fed animals with and without metformin (6.4, C).  In high 
fat fed rats metformin significantly improves microvascular recruitment in the skeletal 
muscle of high fat fed rats compared to high fat diet alone, and restored microvascular blood 
flow to that of control animals (6.4, C).   
The expression of inflammatory and macrophage markers within adipose tissue were not 
different between the high fat fed rats which received metformin and those that did not (6.2).   
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Figure 6.2 – Effect of 4 weeks high fat feeding (41% fat) and metformin treatment on 
(A) body weight and (B) adiposity in high fat fed rats (), and high fat fed rats 
treated with metformin ().  Epididymal fat pads were excised and weighed 
immediately after removal.  Mean wet weight as percentage of body weight is shown for 
each group ± SEM for n = 25-27 rats.  * = p<0.05 indicates significant difference by 
Student’s t-test. 
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Figure 6.3 – Effect of a 4 week 41% high fat diet and metformin treatment on whole body 
insulin sensitivity of high fat fed rats (), and high fat fed rats treated with metformin () 
by hyperinsulinemic euglycaemic clamp.  Data shows means ± SEM for n = 14-17 rats in each 
group.  *** = p < 0.001 indicates significant difference between high fat diet groups with and 
without metformin treatment for GIR measurement by two-way repeated measures ANOVA.   
Table 6.2 - Effect of metformin treatment on metabolic responses 
and insulin sensitivity in high fat fed rats. 
 
Metabolic parameters were measured by performing 10 mU hyperinsulinemic euglycaemic 
clamps in anaesthetised animals, with glucose infusion rate reflecting whole body insulin 
sensitivity.  Muscle glucose uptake was calculated by 2-deoxy-D-Glucose uptake during 
final 45 minutes of clamp procedure.  Data shows means ± SEM for n = 14-17 rats in each 
group. Statistical analysis was performed by Student’s t-test and GIR analysis was 
performined by two-way repeated measures ANOVA.   
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Figure 6.4 – Effect of a 4 week 41% high fat diet and metformin treatment on (A) whole 
body insulin sensitivity, (B) skeletal muscle glucose uptake, and (C) Microvascular 
perfusion in control () and high fat fed rats (), with and without metformin treatment.  
GIR reflects whole body insulin sensitivity during 10 mU hyperinsulinemic euglycaemic 
clamps.  Muscle glucose uptake was calculated by 2-deoxy-D-Glucose uptake during final 45 
minutes of clamp procedure, and microvascular perfusion within skeletal muscle was assessed 
by the metabolism of 1-MX.  Data shows means ± SEM for n = 14-17 rats in each group.          
* = p<0.05, ** = p<0.01, *** = p < 0.001 indicates significant difference within diet groups 
with and without metformin treatment, ## = p<0.01 indicates significant difference between 
high fat and control rats treated with metformin by two-way ANOVA.   
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Table shows relative expression of inflammatory marker mRNA ratio to the 
housekeeper S9 in Sprague Dawley rats fed a 41% high fat diet for 4 weeks 
with and without metformin treatment.  Inflammatory gene expression was 
not found to be altered in the visceral adipose tissue of high fat fed rats treated 
with metformin compared to those without.  Data shows means ± SEM for n = 
5-6 rats in each group.  Statistical analysis was performed by Student’s t-test.   
Table 6.3 – Comparison of inflammatory gene expression in insulin sensitive 
tissues of 4 week high fat diet-fed rats with and without metformin treatment  
 
86 
 
6.4 Discussion 
 
Metformin is the drug of choice therapy for the treatment of insulin resistance in humans.  
This is due to both its effectiveness at controlling blood glucose levels and preventing 
cardiovascular mortality [255, 268, 271].  This study has confirmed that high fat fed rats 
treated with metformin have significantly improved whole body insulin sensitivity and 
muscle glucose uptake compared to high fat diet alone (Table 6.2, Figure 6.3).  This study has 
also confirmed that metformin improves muscle insulin sensitivity in terms of glucose uptake 
during an insulin clamp.  Comparison of GIR of control and high fat fed rats shows that 
metformin treatment in high fat fed rats not only significantly increases whole body insulin 
sensitivity compared to high fat diet alone, but it actually restores and significantly improves 
whole body insulin sensitivity compared to that of control diet-fed animals (Figure 6.4, A).  
Skeletal muscle glucose uptake in high fat fed animals was also significantly improved and 
restored to that of control animals when treated with metformin (Figure 6.4, B).  Comparison 
of microvascular perfusion by 1-MX shows that metformin not only significantly improves 
microvascular blood flow within the skeletal muscle of high fat fed rats, effectively restoring 
it to that of control-fed animals (Figure 6.4, C).  Measurement of inflammatory gene 
expression within the adipose tissue confirmed that 41% high fat feeding does not induce a 
significant inflammatory response and this was not altered by metformin treatmed despite its 
glucoregulatory actions (Table 6.3).  These results confirm that the loss of insulin-mediated 
metabolic and vascular functions are not driven by inflammation and can be restored.        
 
The finding that 4 week metformin treatment can restore microvascular blood flow within 
insulin resistant muscle to that of controls has not yet been reported elsewhere in the 
literature.  The ability to not only improve but restore microvascular blood flow to that of 
controls would have direct consequences for muscle glucose uptake due to enhanced delivery 
of glucose to the myocytes.  Metformin’s ability to improve capillary blood flow so 
completely may be why it is so successful at improving skeletal muscle insulin sensitivity as 
it has been shown that the loss of microvascular blood flow responses is a leading contributor 
in the development of skeletal muscle insulin resistance [86].  These results confirm the 
effectiveness of metformin for the treatment of insulin resistance and that it is a drug 
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treatment that targets multiple aspects of insulin resistance by significantly improving both 
metabolic and vascular dysfunction.   
 
In conclusion, this study confirms the complete restoration of insulin’s metabolic and 
vascular effects on muscle by metformin treatment, and demonstrates that this action does not 
require an anti-inflammatory action in adipose tissue.  This does not rule out the possibility 
that in situations where inflammation contributes to insulin resistance, that metformin might 
have additional benefits for muscle or whole body insulin sensitivity.  However, it suggests 
that metformin’s actions in muscle and its vasculature are more likely by opposing the 
‘lipotoxicity’ effects on insulin signalling induced by altered plasma and whole body lipid 
distribution.  It remains to be seen whether there is any additional benefit for muscle insulin 
sensitivity in a more complex model of insulin resistance, perhaps reflecting human obesity, 
where inflammation and dyslipidemia may be present together.   
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CHAPTER 7 
 
 
 
DISCUSSION 
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7.1  Findings and General Discussion 
 
The increasing prevalence of obesity has become a significant problem.  This is due to its 
strong association with a number of health conditions including insulin resistance, Type 2 
Diabetes, and cardiovascular disease [16, 18, 20, 116, 141].  Many studies have induced 
obesity in animal models in order to investigate these conditions and gain a greater 
understanding as to the mechanisms and actions regulating their induction [86, 138, 176, 181, 
193, 210].  Although genetic models of obesity are regularly used [129, 189, 235, 278, 279], 
diet-induced obesity has been favoured by many as it provides a more accurate representation 
of the development of obesity and its associated health complications [26, 188, 202, 204, 212, 
220].  Dietary interventions to induce obesity have primarily focused on increased fat 
content.  This is largely due to increased dietary fat being seen as a significant contributing 
factor towards the development of obesity in humans and animals [204, 279, 280].  A number 
of studies have investigated variable degrees of fat on obesity and metabolic responses in 
rodent models [26, 86, 138, 180, 200, 209, 215, 281].  In both rats and mice, moderate to high 
fat feeding within the literature has proven successful at producing significant obesity 
accompanied by associated insulin resistance, with diets containing a higher fat content or 
given for longer interventions being shown to produce both a greater degree of adiposity and 
metabolic impairment [26, 86, 180, 198, 202].   
 
Results presented in Chapters 3 and 4 have shown varied responses to high fat dietary 
interventions in rats.  A ‘moderate’ high fat diet in which 41% of the calories were derived 
from fat, produced significant adiposity in rats after a 4 week dietary intervention (Chapter 
3).  High fat fed rats showed approximately a 50% increase in adipose tissue weight 
compared to control animals, with this increased adiposity associated with impaired insulin 
sensitivity of both metabolic and vascular responses.  Many obesogenic studies in both mice 
and rats favour diets with considerably higher fat contents in which more than half of the total 
calories are derived from fat [26, 72, 86, 176, 198, 200, 201, 203, 209, 282].  Diets in which 
approximately 58% of the calories were derived from fat produced significant adiposity in 
rats after a 4 week intervention which was approximately 50% greater than that of control 
animals.  Surprisingly, this adiposity was not associated with the same metabolic impairments 
present in rats on the 41% fat diet (Chapter 4) or those reported in the literature [86, 176].  An 
90 
 
even more surprising finding was that extending this dietary intervention to 12 weeks of high 
fat feeding did not produce a phenotype typical of diet-induced obesity in our rat model.  In 
fact this 12 week high fat intervention showed that adiposity seen following 4 week feeding 
was not maintained with longer dietary intervention.  Therefore this higher fat diet only 
produced transient adiposity which was not maintained long-term.  Despite its reported 
success within the literature [26, 86, 117, 120, 176, 177, 203], a 58% high fat diet was shown 
to be ineffective at inducing an obese and insulin resistant phenotype in our rat model 
(Chapter 4).   
 
Results from high fat feeding interventions in chapters 3 and 4 have shown that although 
some high fat diets are successful at producing an obese and insulin resistant phenotype in 
rats, they do not necessarily deliver these responses consistently or maintain them over long 
interventions.  From the results obtained, it is clear that from the two high fat diets used, the 
diet with the lower fat content (41% fat) was more effective than the higher fat diet (58% fat) 
at producing obesity (75% versus 50% increase) and insulin resistance in rats.  Although this 
result was initially surprising due to the reported success of high fat feeding for increasing 
adiposity within the literature, it raised the question of diet palatability playing a key role in 
inducing hyperphagia and thus obesity in rat models.  The high fat diet may not be palatable 
enough to produce and maintain a significant degree of obesity in rats as dietary intervention 
lengthens.  This explains why adiposity was transient with the 58% high fat diet and only rats 
given short-term interventions showed significant adipose tissue accumulation.  Therefore 
use of diets high in purely fat has shown that alternative interventions to induce diet-induced 
obesity in rat models should be considered.  A cafeteria-style diet based on a variety of highly 
palatable snack-food items has not only shown to produce significant hyperphagia and weight 
gain in rat models, but also provides a more realistic representation of poor dietary health 
often present in obese humans [188, 220, 222, 227, 228].   
 
As shown in Chapter 5, the use of this highly variable cafeteria-style diet based on palatable 
and calorie dense snack food items produced excessive adiposity and significant insulin 
resistance after a 4 week intervention.  The degree of adiposity produced with this diet 
equated to approximately a 120% increase in adipose tissue accumulation compared to 
controls.  Long-term intervention showed that adiposity remained significantly elevated and 
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insulin sensitivity was still impaired after 12 weeks.  Direct comparison of these results to 
those obtained with 58% high fat feeding (Chapter 4) over both short and long-term 
interventions show that the use of this palatable and variable cafeteria-style diet is superior at 
inducing an obese and insulin-resistant phenotype in rats compared to a diet high in fat alone.  
Comparison of adiposity after a 4 week intervention shows that cafeteria diet-fed rats 
possessed approximately an 80% increase in adipose tissue weight compared to the adiposity 
of 58% high fat-fed rats, whilst after 12 weeks cafeteria diet rats possessed a 150% increase 
in adiposity compared to matched high fat fed rats.     
 
Therefore these results show that both diet variability and palatability are important 
components to consider for the induction of diet-induced obesity in rats, and this conclusion 
is consistent with studies conducted by Sampey [188], Prats [232], Shafat [227], Rogers 
[222], and Martire [220] using similar dietary interventions.  However this thesis adds to the 
current research due to its ability to directly compare the degree of obesity and insulin 
resistance obtained with a cafeteria-style diet to that obtained with commercial high fat 
feeding over both short and long-term time-points in rats.   
 
Obesity has frequently been associated with inflammation within the literature, and this 
obesity-induced inflammation has regularly been reported to contribute towards the metabolic 
dysfunction present in insulin resistant conditions [18, 19, 100, 118, 148, 181].  However 
despite this association, the mechanisms surrounding its induction and ability to impair 
insulin sensitivity is not well understood.  Much of the work in regards to obesity-induced 
inflammation has been conducted in high fat fed mouse models [26, 27, 117, 120, 123, 124, 
187] with similar studies in rats [185, 188, 210] outnumbered by comparison.  Reasons for 
this preference have not been addressed within the literature, however rat models allow for 
more thorough examination of physiological systems such as vascular responses within 
skeletal muscle [23, 32, 86, 87].  As a result of the strong association between obesity and 
insulin resistance, the inflammatory markers chosen in this thesis included those that had 
shown the ability to alter insulin-mediated responses within the vasculature and skeletal 
muscle [72, 122, 123, 126, 127, 129, 142, 143, 187, 253].   
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Diet-induced obesity in mice has shown that a number of inflammatory and macrophage 
markers are significantly increased within visceral adipose tissue within 1 week of high fat 
feeding, with some markers significantly expressed within 3 days.  However a greater 
significant inflammatory response was seen in the adipose tissue, liver, and skeletal muscle 
after long-term intervention consisting of 16 weeks in which obesity was the most 
pronounced [26].  Some of these markers include TNFα, iNOS, MCP-1, and EMR-1 which 
were the inflammatory factors selected to be investigated in this thesis.  Significant 
inflammatory responses within the literature have been reported as large fold changes such as 
2-3 fold increases gene expression within tissues, with some studies reporting expressions 
that are as high as 10 or 20 times higher [26, 71, 124].   
 
From the dietary studies conducted in this thesis there was a notable absence of inflammatory 
expression in both models of high fat feeding regardless of obesity and insulin resistant 
status.  However what was especially surprising was that despite the excessive adiposity 
present in cafeteria diet-fed rats, inflammatory factors were not found to be significantly 
expressed at either 4 or 12 week time-points.  What is suggested from this study is that 
obesity and insulin resistance can occur independently of inflammation, and that although 
obesity-induced inflammation may in turn influence insulin-mediated responses if induced, it 
may not play an important role in its initial induction.  Nor does improvement to insulin 
sensitivity alter the expression of inflammatory factors within tissues.  Although further 
confirmation and examination of inflammation and insulin resistance in diet-induced obesity 
is needed, regular reporting of its association within obese and insulin resistant conditions 
should be reconsidered if additional findings support this conclusion.   
 
The examination of other tissues such as liver could provide further evidence of 
inflammatory status with dietary interventions.  Studies conducted by Lee [26] and Sampey 
[188] have previously investigated dietary induced liver inflammation in mice and rats 
respectively.  Both studies report significant inflammation with increased macrophage 
infiltration and expression of pro-inflammatory markers such as TNF-α, IL-6, IL-1β, iNOS 
and MCP-1 in the liver and adipose tissue of  16 week high fat fed mice [26] and 15 week 
cafeteria diet-fed rats [188].   However as there was a significant lack of inflammatory 
response within the adipose tissue of 12 week high fat and cafeteria diet-fed rats from the 
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studies conducted in this thesis, the presence of significant liver inflammation is therefore 
unlikely in these animals, however liver tissue should be considered in further experiments.  
In addition to liver, further examination of adipose tissue depots may also provide additional 
insight into inflammatory expression in obesity.  There has been notable interest in the 
inflammatory expression within fat depots surrounding blood vessels (perivascular adipose 
tissue) within the literature [283-288].  Perivascular adipose tissue has been shown to produce 
a wide variety of adipokines, with a number of studies having shown significant expression 
of proinflammatory cytokines and chemokines within this fat depot [283, 284, 287].  As 
previously discussed within the introduction of this thesis, a number of proinflammatory 
factors have been shown to intervene with the highly coordinated actions of the vasculature 
and alter vascular responses [72, 126-128, 143, 160, 161].  As a result fat depots both within 
and surrounding the heart have been of interest to those investigating the links between 
inflammation and heart disease [285, 287].  Cardiovascular disease is highly prevalent in 
obese and insulin resistant individuals [12, 100, 141, 289] and as previously discussed 
vascular dysfunction, especially within the microvasculature, is significant in the 
development of impaired skeletal muscle insulin sensitivity [16, 23, 32, 86, 138].  Therefore 
there have been a number of studies that have investigated the relationship between 
proinflammatory perivascular adipose tissue, vascular function, and insulin sensitivity with 
many suggesting that this fat depot may contribute more directly to the pathogenesis of the 
metabolic syndrome [285, 287, 288, 290].   
 
In mouse studies of obesity-associated inflammation the degree of adiposity is often reported 
to be 3 or more times higher than that of control animals.  This degree of adiposity is 
comparable to that obtained in the 12 week cafeteria diet-fed rats, however these rats did not 
show a significant inflammatory response.  Therefore the lack of inflammatory expression 
despite significant and comparable adiposity is intriguing.  A range of inflammatory factors 
have be shown to be significantly expressed within both the adipose tissue and skeletal 
muscle of obese mice [26, 27, 117], however interestingly this response does not translate 
across in rat models of diet-induced obesity.  This raises the possibility that rats are much 
more resistant to the development of inflammation and may possess mechanisms to protect 
against developing obesity-associated inflammation in particular.  As the results obtained 
from the cafeteria-diet study show, both short and long-term interventions produced 
excessive obesity in rats however there was no increased expression of inflammatory factors 
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within the adipose tissue of these animals compared to controls (Chapter 6).  Therefore it is 
possible that straightforward obesity alone is not enough to trigger an inflammatory response 
and that other factors in association to obesity may be required for this to occur or to initiate 
an inflammatory outcome.   
 
7.2  Implications 
 
Both insulin resistance and inflammation are complex disease states that involve a number of 
highly controlled signalling pathways [18, 19, 43, 53, 56, 96, 100, 164, 199, 291-295].  There 
has been much research in investigating the involvement of numerous cells and proteins on 
altering these pathways in the development of obesity-induced inflammation [112, 113, 156, 
247, 295-299]; however despite this a number of specific mechanisms such as when and how 
inflammation is induced in diet-induced obesity, and a detailed time-course of how its 
induction impacts on vascular and muscular insulin-mediated responses, is still not fully 
understood [26, 117, 148, 198, 210].  What is clear from previous research is that the 
induction of inflammatory signalling, especially within diet-induced obesity, may be reliant 
on a number of other signals and responses to occur before inflammation can be initiated.  
Due to the strong association between obesity and inflammation, the adipose tissue has been 
highlighted as an important site in which the regulation of inflammatory expression is 
conducted [19, 27, 164, 165, 300].  The view that adipose tissue is solely a site for energy 
storage is now outdated.  Adipose tissue is now recognised as a complex and active organ 
capable of multiple functions and that, in addition to its primary role in lipid storage, also 
contributes towards endocrine function [163, 165].  The adipose tissue is known to secrete a 
number of hormones including leptin and adiponectin which are important for metabolic and 
energy homeostasis [163-165].  In addition to this the adipose tissue also secretes or induces a 
number of inflammatory factors including cytokines and macrophage markers.  However the 
exact mechanisms and pathways by which this occurs are still not fully understood.     
 
Due to its primary role for energy storage, the adipose tissue is required to respond rapidly to 
changes in nutrient availability and react accordingly [166].    In times of excess nutrient 
availability, adipocytes are required to undergo hypertrophy and at times hyperplasia to 
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accommodate for additional energy storage.  Therefore the tissue requires mechanisms in 
place that allow for regular and ongoing remodelling of the tissue in order to meet these 
demands.  At times in which nutrient availability and storage requirements are regularly 
needed in excess (such as during high fat feeding or diet-induced obesity), this process of 
hypertrophy and tissue remodelling would be required at a much higher rate [166].   
 
Adipose tissue regulation and remodelling, especially during expansion in obesity, has gained 
interest in regards to the tissue’s inflammatory status and associated health implications and 
has thus become an important topic for discussion [165, 168, 301-303].  Adipose tissue goes 
through an ongoing process of tissue remodelling and expansion during the development of 
obesity or rapid lipid storage in order to meet with storage demands.  However it has been 
shown that adipose tissue can undergo both healthy and unhealthy tissue expansion.  
Unhealthy tissue expansion has been linked to pathological and metabolic dysfunction often 
reported in obese and diseased states, such as inflammation [165].  The exact reasons and key 
influencing factors for why adipose tissue may expand in healthy or unhealthy ways is not 
fully understood and requires further in-depth examination, however some mechanisms have 
been hypothesised.   
 
During early or short-term lipid storage adipose tissue will undergo expansion to meet with 
storage demands, however if storage demand increases chronically the tissue can undergo 
remodelling and hyperplasia [165].  Under healthy expansion conditions angiogenesis may 
also occur to meet and provide the tissue with a sufficient blood supply and oxygen delivery 
[166].  However excessive lipid storage and rapid expansion of the adipose tissue in a short 
amount of time may result in significant hypertrophy of adipocytes without additional 
remodelling which includes adequate hyperplasia and angiogenesis.  This can result in 
insufficient vascular or microvascular branching to allow adequate blood flow and oxygen 
delivery to the adipocytes.  Excessive hypertrophy would also reduce the diffusion distance 
and oxygen availability within the adipocytes themselves.  During significant hypertrophy, 
adipocytes may reach a degree of expansion in which the diffusion of oxygen into the cell is 
limited.  Adipocytes have been found to reach sizes up to 150-200 µm in diameter during 
obesity, which is larger than the average diffusion distance of oxygen across tissues [166, 
304, 305].  Both of insufficient blood supply and poor oxygen diffusion can result in a 
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hypoxic environment occurring within adipocytes, which in turn increases the expression of 
Hypoxia Inducible Factor 1α (HIF-1α) [167, 168, 303, 305].  HIF-1α has been identified an 
early upstream initiator of inflammatory responses, and thus this hypoxic environment and 
activation of HIF-1α within the adipose cell can activate inflammatory factors including the 
induction of macrophages to occur within the tissue [165, 166, 168].  Some adipocytes may 
also become so poorly oxygenated that they become necrotic which in turn has been shown to 
activate an increased inflammatory responses locally within the tissue [166, 168, 170, 171].  
Therefore the development of hypoxia within the adipose tissue is potentially a key factor 
underlying the induction of inflammatory responses within the tissue itself, leading to the 
reported association of inflammation with obese conditions [305].  Constant remodelling and 
stress within the adipose tissue due to the need to meet storage demands may also result in 
fibrosis which can impair tissue expansion and be another contributing factor to an unhealthy 
adipose tissue environment [166, 168, 306].  Fibrosis within the adipose tissue has also been 
highlighted, in addition to hypoxia, as a key factor important for the initiation of local 
inflammation within the tissue [166].            
 
Despite this, the regulation of adipose tissue expansion is still not greatly understood and the 
mechanisms managing these responses as to whether dysfunctional expansion will occur are 
still unknown.  However, adipose tissue expansion has gained interest due to the potential 
health implications that unhealthy expansion may have both within the tissue and 
systemically [165, 168, 301-303].  Because of this, dysfunctional adipose tissue expansion 
and hypoxia have been identified as important factors involved in the initiation and 
development of obesity-associated inflammation regularly reported within the literature.  
Therefore healthy expansion within the adipose tissue may provide an explanation for the 
lack of inflammatory response in our rat models of diet-induced obesity.  However further 
confirmation is needed in order to draw a reliable conclusion.  Histological assessment of the 
adipose tissue, especially in regards to adipocyte size, macrophage content, and HIF-1α 
expression, would provide additional information as to the health and inflammatory status of 
the tissue and inclusion of this measurement would have provided considerable weight 
towards the conclusions of this thesis.  Further investigation into HIF-1α and adipose tissue 
expansion and blood flow would be beneficial for future studies into diet-induced 
inflammation as there is potential possibility that the inflammatory status within the adipose 
tissue is variable during periods of expansion, and that adipose tissue inflammation may be 
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able to directly affect other responses such as vascular signalling during this expansion 
process if unhealthy adipose tissue expansion occurs.   
 
7.3  Limitations 
 
The main limitation and weakness of the current thesis is the measurement of inflammation within 
this study.  A more detailed and comprehensive assessment of inflammation would provide 
further evidence to support the final conclusions of this thesis.  In the gene expression studies 
only four inflammatory markers were investigated in this thesis which does result in 
limitations within the study and thus its conclusions.  Future experiments should be expanded 
to investigate a wider range of inflammatory markers which have also been association with 
obesity and insulin resistance such as IL-6 [18, 118, 123, 124, 130], IL-10 [130], NF-Kβ [18, 
112], HIF-1α [168, 200, 303, 305, 307] and a greater number of macrophage markers such as 
CD11c [208] and CD68 [123, 308].  In addition, the inflammatory gene expression studies 
could be further strengthened by the use of positive controls.  The presence of a controlled 
inflammatory response would have allowed a direct comparison of the degree of 
inflammation obtained and provided additional support towards the conclusions of this thesis.  
Therefore the lack of positive inflammatory controls is currently a weakness within the study 
and should be included in any further experiments.  Another point to note is that although the 
gene expression studies were powered to detect a change of 50% or greater within the current 
thesis, the statistical power and sample sizes for the gene expression studies should be 
reviewed in light of the data obtained. There is the potential that these experiments may be 
incorrectly powered and thus limit the effectiveness of identifying true significant 
inflammatory changes and influencing the conclusions of this thesis.  The examination of the 
full cohort of animals instead of a subset (especially within Chapter 3) should be considered 
in any future experiments.  Re-evaluating the statistical power and sample size needed to 
detect significant changes would be important for any further examination of inflammatory 
gene expression.   
 
Additional methods of evaluating inflammatory responses such as flow cytometry, histology, 
and investigating other fat depots and tissue sources are all measurements which would also 
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add further weight to the gene expression studies.  The use of flow cytometry would be a 
powerful technique to provide additional data as to both the presence and subset of immune 
cells, including the presence of circulating inflammatory cells within the plasma.  In addition, 
the use of histology and immunofluorescence analysis would allow for direct examination of 
the infiltration of inflammatory cells within tissues such as skeletal muscle and adipose 
tissue.  Histology analysis would also allow for the degree of lipid accumulation, 
hypertrophy, and hyperplasia to be examined within the adipose tissue and provide additional 
insight into the health and expansion of the tissue itself.     
 
As well as including additional techniques to assess inflammation, expanding the sites and 
tissue samples analysed would also add further evidence to this thesis.  The use of the 
epididymal fat pad depot as the site for adipose tissue inflammation is not entirely a poor 
choice as epididymal fat pad has been routinely examined by others within the literature due 
to its visceral nature, ease of access for removal, and significant lipid accumulation [26, 86, 
138, 176, 188].  Visceral fat has been strongly linked to metabolic disease and increased 
inflammatory expression within the literature [118, 300, 309-312], however it is important to 
note that investigating other fat and tissue depots could provide additional insight into 
inflammatory expression in obesity.  Therefore the use of only skeletal muscle and visceral 
adipose tissue is currently a weakness within the study and other tissue sources, such as liver 
and other fat depots such as perivascular adipose tissue, which have also shown increased 
inflammatory expression linked to obesity and impaired insulin sensitivity [26, 142, 154, 188, 
285, 287, 288, 290], should be investigated in future experiments.   
 
Providing other measurements in addition to body weight and adiposity could offer further 
insight into the body composition and potential overall health of the animals given different 
dietary interventions, and thus the effectiveness of these dietary interventions on producing a 
phenotype more typical to that of human obesity.  Limitations of only body weight and 
epididymal fat pad measurements also do not take in to account the lean mass or the natural 
growth changes that may occur between animals within the studies.  Despite the use of age-
matched controls within all experiments, this may be of importance as the experiments have 
been conducted in relatively young animals.  Although investigating the effects of dietary 
intervention and high fat feeding within younger animals is relevant due to the increasing rise 
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of childhood obesity and insulin resistance [8, 10, 313, 314], dietary intervention in young 
animals may be a potential confounding factor in regards to the true degree of weight gain 
and adiposity that is obtained due to growth that occurs within this age range.  Performing 
comparative studies in older, more established animals should be considered for future 
studies and would provide additional information in regards to adiposity and the degree of 
inflammation and impaired insulin sensitivity obtained with dietary intervention. 
 
In addition to the studies being conducted in younger animals only male rats were chosen to 
study within these experiments.  The majority of our research group’s characterisation in 
models and measurement of vascular responses has been performed in male rats [23, 86, 126, 
138, 143, 176], therefore conducting these experiments in all-male animals allows for a direct 
comparison between studies previously conducted within our group.  In addition, the 
experiments within this thesis attempted to gain a greater understanding of underlying 
mechanisms of action between obesity-induced inflammation and insulin resistance, so at this 
stage the inclusion of both sexes currently adds additional variability.  The discovery of a 
significant association or link would be preferable before the study is broadened to include 
more additional variables, however it is possible for sex-related differences and responses to 
occur and the inclusion of both sexes within experimental studies is valid and should be 
considered in future investigations.   
 
There were also notable difficulties with the use of high fat diets within the experiments of 
this thesis.  Both the 41% and 58% high fat diets have been used previously in studies within 
our research group with both diets proving to be successful at impairing insulin sensitivity 
after similar dietary interventions [86, 138, 176, 180].  Unfortunately the results from 
previous studies using the 58% high fat diet [86, 176] could not be replicated within this 
thesis and in fact produced problematic results in regards to adiposity and insulin sensitivity 
with long-term dietary use.  As the use of the 58% high fat diet was proving difficult it was 
decided to abandon commercial laboratory diets in favour for a cafeteria-style diet consisting 
of high caloric and palatable snack food items.  However it would be important to further 
investigate the 58% high fat diet in more detail including monitoring food intake to 
investigate whether diet palatability and caloric intake can explain the lack of adiposity in 
animals fed this diet over longer interventions.  Without this measurement it can only be 
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proposed that calorie intake and food consumption was lower with this diet and that 
palatability of the diet may be a significant contributing factor.  Inclusion of the 41% high fat 
diet in an independent cohort of rats during this investigation may also provide a useful 
comparison, especially in regards to the degree of adiposity and impaired insulin sensitivity 
that is obtained.          
 
Another weakness within this thesis is that microvascular perfusion was not measured in all 
rat experiments compared to skeletal muscle insulin sensitivity.  Microvascular perfusion has 
previously been examined by our research group with impaired microvascular blood flow 
found to be an early defect in the development of impaired insulin sensitivity [32, 86, 138].  
Therefore the absence of skeletal muscle insulin resistance in short and long-term high fat fed 
rats in Chapter 4 implies that there is no additional vascular defect also present, however 
inclusion of this measurement would have provided confirmation.  Microvascular perfusion 
was also not measured in cafeteria diet-fed animals which did show significant impairment to 
skeletal muscle insulin sensitivity and is thus currently a limitation within the study as this 
measurement would have provided a more comprehensive view of the dysfunction and 
impaired insulin sensitivity of these animals, comparable to the high fat studies conducted in 
Chapters 3 and 6.  Also of note is that although insulin-mediated glucose uptake in skeletal 
muscle has been a routine measurement, the inclusion of insulin-mediated glucose uptake 
within adipose tissue could have provided additional evidence of adipose tissue insulin 
sensitivity.  This would have provided additional support towards the conclusions of this 
thesis, especially if the adipose tissue was found to show significant impairment to insulin 
sensitivity without increased inflammatory expression.   
 
 
7.4  Conclusions 
 
Results from this thesis have shown a number of findings in regards to diet-induced obesity 
and obesity-associated inflammation in rats.  Firstly, dietary interventions to generate diet-
induced obesity should be considered carefully.  Use of commercial high fat diets in rats has 
shown variable results in regards to producing an obese and insulin resistant phenotype.  Diet 
101 
 
variation and palatability have been shown to be important factors to consider in regards to 
generating significantly overt diet-induced obesity in rats.  Secondly, inflammation does not 
appear to be an important contributing factor in regards to the development of obesity and 
insulin resistance in rats as obesity and insulin resistance can develop, and be restored, 
without the presence of increased inflammatory expression.  Results obtained in this thesis 
have indicated that obesity-associated inflammation may not be present in all states of obesity 
and insulin resistance, and that these conditions may occur without inflammation present, 
however further assessment of inflammatory expression in diet-induced obesity is required in 
order to support this conclusion and make further claims. Although inflammatory factors may 
contribute to impaired insulin sensitivity when induced, it is suggested in the current study 
that they may not be key factors in driving an insulin resistant response in vivo.  The lack of 
significant inflammatory expression despite overt obesity suggests a further hypothesis that 
rats may possess protective mechanisms preventing inflammatory induction in response to 
significant obesity.  As such, adipose tissue expansion has been highlighted as a potential 
mechanism that may regulate inflammatory induction in response to diet-induced obesity, 
however further validation of this theory is required.  The mechanisms surrounding healthy 
and dysfunctional expansion in addition to inflammatory induction are still not well 
understood and also require further research.   
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